Gene Expression Signature and Pro-Angiogenic Function of Tie2-Expressing Macrophages by Pucci, Ferdinando
Open Research Online
The Open University’s repository of research publications
and other research outputs
Gene Expression Signature and Pro-Angiogenic
Function of Tie2-Expressing Macrophages
Thesis
How to cite:
Pucci, Ferdinando (2010). Gene Expression Signature and Pro-Angiogenic Function of Tie2-Expressing Macrophages.
PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2010 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Ferdinando Pucci, MSc
Gene expression signature and pro-angiogenic function of 
Tie2-expressing macrophages
PhD candidate
In fulfillment of the Open University requirements for the degree of Doctor of 
Philosophy in Molecular and Cellular Biology
Director of studies External supervisor
Michele De Palma Claire Lewis
Vita-Salute San Raffaele University 
Milan, Italy
18 October 2010
p a te  oj. 5ub rw tss iokv : 30 ^DfD
Date oj A w ard * October Tx^io .
ProQuest Number: 13837622
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13837622
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Table of Contents
Illustration Index....................................................................................................... V
Index of Tables....................................................................................................... VII
Abstract 
Introduction
1 Innate immunity: historical perspective.................................................................. 3
1.1 Reticulo-endothelial system............................................................................ 4
1.2 Mononuclear phagocyte system..................................................................... 6
1.2.a Embryonic Mcps and the mononuclear phagocyte system...................... 9
1.3 Local proliferation of resident tissue mononuclear phagocytes....................10
1.4 Monocyte subsets..........................................................................................10
1.5 Heterogeneity of mononuclear phagocytes.................................................. 12
1.6 Acute versus chronic inflammation................................................................13
2 Inflammation, angiogenesis and cancer............................................................... 15
2.1 The hallmarks of cancer................................................................................ 15
2.2 Tumor angiogenesis...................................................................................... 16
2.3 Inflammation and cancer............................................................................... 17
3 Myeloid cells and tumor angiogenesis......................................................  19
3.1 Monocytes/Macrophages.............................................................................. 20
3.2 Polymorphonuclear phagocytes.................................................................... 23
3.3 TIE2-expressing macrophages (TEMs)........................................................ 25
3.3.a TEMs are pre-committed to a angiogenic function................................27
3.3.b Exploiting TEMs to deliver therapeutics to tumors................................29
3.3.C Human TEMs..........................................................................................30
4 TIE2 receptor.........................................................................................................31
4.1 Signalling mechanism.................................................................................. 31
4.2 Regulation of vascular homeostasis............................................................. 32
4.3 Regulation of TEM biology............................................................................34
Aim of the work 
Results
5 Isolation of highly purified tumor macrophage subsets........................................39
5.1 Identification of the best-performing cell sorting formula..............................39
5.2 Validation of sorted tumor macrophage subsets.......................................... 42
6 Tumor TEMs are monocytes/macrophages expressing a distinguishing gene 
signature..................................................................................................................43
6.1 Genes highly expressed in TEMs................................................................. 44
6.2 Morphological analysis of tumor macrophage subsets................................ 45
6.3 Genes differentially expressed between TEMs and TIE2- TAMs................ 46
6.3.a Statistical model.....................................................................................48
6.3.b Validation by FACS and IF staining.......................................................49
6.4 TEMs are refractory to pro-inflammatory stimuli...........................................52
7 Blood TEMs are a subset of monocytes.............................................................. 54
7.1 TEMs express resident monocyte marker profile......................................... 54
7.2 Common gene signature of circulating resident monocytes and tumor- 
infiltrating TEMs...................................................................................................54
8 Tie2 knock down in hematopoietic cells...............................................................56
8.1 Identification of the most effective RNAi sequence against Tie2................. 56
8.2 Constitutive expression of bicistronic amiR impairs cell growth in-vivo and 
in-vitro..................................................................................................................59
9 Conditional Tie2 knock down in mature hematopoietic cells............................... 62
9.1 Tie2 knock down in primary cells.................................................................. 63
9.2 The conditional gene silencing platform is safe in vivo................................ 64
9.3 Tie2 knock down in tumor TEMs impairs angiogenesis........................... ....68
Discussion
10 TEMs are distinct from ECs................................................................................73
11 Overlapping function and phenotype between TEMs and other mononuclear 
subsets.....................................................................................................................74
12 Functional considerations...................................................................................75
12.1 Extra-cellular matrix and TEMs...................................................................75
12.2 Soluble mediators........................................................................................76
12.3 TEMs as cellular chaperones......................................................................77
12.4 Miscellanea..................................................................................................78
13 TEM precursors.................................................................................................. 79
14 Role of TIE2 in TEMs..........................................................................................80
Appendix -  RNA interference
15 The micro-RNA world..........................................................................................85
16 Exploiting RNAi...................................................................................................85
Material and methods
17 Transgenic mice..................................................................................................89
18 Lentiviral vectors................................................................................................. 89
19 Hematopoietic stem/progenitor cell (HSPC) isolation, transduction and 
transplantation.........................................................................................................90
19.1 In vivo doxycycline administration..............................................................91
19.2 Magnetic Resonance Imaging (MRI)..........................................................91
20 Tumor models..................................................................................................... 92
20.1 Spontaneous MMTV-PyMT tumors............................................................. 92
20.2 N202 mouse mammary carcinoma............................................................. 92
21 Flow cytometry....................................................................................................92
21.1 Antibodies.................................................................................................. 93
21.2 Tumors.........................................................................................................93
21.3 Peripheral blood.......................................................................................... 94
22 Flow sorting........................................................................................................ 94
22.1 Tumor-derived TEMs, TIE2-TAMs and ECs.............................................94
22.2 GR1+ CD11b+ myeloid derived suppressor cells (MDSCs).......................95
22.3 Peritoneal macrophages (PMs).................................................................. 95
22.4 Resident and inflammatory monocytes..................................................... .96
23 Immunofluorescence staining (IFS) and confocal microscopy.......................... 96
23.1 In vivo labeling of vascular perfusion.........................................................97
23.2 Quantification of vascular parameters........................................................ 97
23.3 Antibodies......................................................................................  98
24 Colony-forming cell (CFC) assays..................................................................... 98
25 May-Grunwald-Giemsa staining.........................................................................99
26 Gene expression analyses and statistical analysis............................................99
26.1 Comparison of gene expression profiles between tumor-derived cells vs. 
circulating monocytes..........................................................................................99
27 RNA and DNA extraction and qPCR............................................................... 100
27.1 Gene expression (mRNA)......................................................................... 100
27.1.a Freshly isolated TEMs, TIE2-TAMs, MDSCs, PMs and ECs 100
27.1.b In vitro stimulation of TEMs, TIE2- TAMs and PMs with Th1 and Th2 
cytokines...................................................................................................... 101
27.1.C Circulating inflammatory and resident monocytes.............................101
27.2 Small RNA (including artificial micro RNA) analysis.................................102
27.3 Vector copy number analysis....................................................................102
27.4 Collection of raw data and determination of gene expression and LV copy 
number.............................................................................................................. 103
27.5 Calculation of PCR efficiency....................................................................103
IV
27.6.a TEMs vs TIE2- TAMs and Ly6C- vs Ly6C+ monocytes...................104
27.6.b OFP+ vs. OFP- TEMs...................................................................... 105
27.6.c Hematopoietic stem/progenitor cell cultures......................................105
Acknowledgements...............................................................................................106
Acronym Index...................................................................................................... 107
Author's publications.............................................................................................111
Bibliography....................................  113
Illustration Index
Illustration 1: Paul Ehrlich and Ilya Metchnikoff.........................................................3
Illustration 2: The reticuloendothelial system (RES) of Aschoff................................ 4
Illustration 3: The mononuclear phagocyte system in mice...................................... 7
Illustration 4: Acquired Capabilities of Cancer.........................................................16
Illustration 5: The Balance Hypothesis for the Angiogenic Switch.......................... 17
Illustration 6: Model for the link between inflammation, angiogenesis and cancer 18
Illustration 7: TEMs in a tumor section. Immunofluorescence staining..................27
Illustration 8: TEM depletion experiment................................................................. 28
Illustration 9: Schematic representation of the domain organization of the TIE
receptors.....................................................  31
Illustration 10: Model for Angiopoietin-Mediated TIE2 Signaling............................ 33
Illustration 11: Identification of the best-performing cell sorting formula for TEM
isolation.................................................................................................................... 40
Illustration 12: Flow cytometry analysis and sorting of TEMs from N202 tumors
grown in Tie2p/e-GFP transgenic mice................................................................... 4.1
Illustration 13: Validation of sorted TEMs, TIE2- TAMs and ECs by gene 
expression analysis..................................................................................................42
Illustration 14: TEMs robustly express typical myeloid genes, but low to negligible
V
amounts of EC genes............................................... 43
Illustration 15: Genes highly expressed in TEMs and grouped by function 44
Illustration 16: Morphology (May-Grunwald-Giemsa staining) of TIE2- TAMs and
TEMs....................................................................................................................... 45
Illustration 17: One-dot-one-gene representation of the expression profile of TEMs,
TIE2-TAMs, ECs, MDSCs and peritoneal macrophages...................   .46
Illustration 19: Flow cytometric analysis of TAM subsets........................................51
Illustration 18: Confocal immunofluorescence analysis of TAM subsets................50
Illustration 20: In vitro stimulation of peritoneal macrophages, TEMs and TIE2-
TAMs with Th1 and Th2 cytokines...........................................................................52
Illustration 21: Flow cytometry analysis of the blood of Tie2p/e-GFP transgenic
mice......................................................................................................................... 53
Illustration 22: Genes expressed either differentially or not between resident and
inflammatory monocytes...........................................  55
Illustration 23: Design of LV constitutively expressing artificial micro-RNAs and a
marker gene.............................................................................................................56
Illustration 24: Selection of siRNA sequences against TIE2 in vitro....................... 58
Illustration 25: In vivo counter-selection of cells transduced with constitutively
expressing amiR LVs...............................................................................................59
Illustration 26: In-vitro counter-selection of LV carrying amiR155 cassette 61
Illustration 27: Conditional LV platform for amiR expression.................................. 63
Illustration 28: Ex vivo validation of conditional Tie2 gene knock down................. 65
Illustration 29: The conditional gene silencing platform is safe in vivo................... 66
Illustration 30: Efficient de-targeting of amiR expression from BM HSCs in vivo...67 
Illustration 31: Efficient conditional Tie2 gene knock down in tumor-infiltrating
myeloid cells............................................................................................................ 68
Illustration 32: Conditional Tie2 gene knock down in TEMs inhibits angiogenesis
VI
myeloid cells............................................................................................................ 68
Illustration 32: Conditional Tie2 gene knock down in TEMs inhibits angiogenesis
and impairs blood vessel functionality.....................................................................70
Illustration 33: Morphometric analysis of amiR-expressing cells and their
association with blood vessels in tumors................................................................ 71
Illustration 34: Model of ANG2-TIE2 interactions modulating the pro-angiogenic
activity of TEMs........................................................................................................83
Illustration 35: The miRNA processing pathway..................................................... 86
Index of Tables
Table 1: Number of colony forming cells (CFC) arising from sorted TEMs and
TIE2-TAMS............................................................................................................. 43
Table 2: Genes up-regulated in tumor-derived TEMs as compared to TIE2- TAMs.
................................................................................................................................. 48
Table 3: Genes down-regulated in tumor-derived TEMs as compared to TIE2-
TAMs........................................................................................................................ 48
Table 4: Percentages of NGFR+ blood leukocytes measured by FACS at the
indicated time points. U-test: Mann-Whitney test................................................... .60
Table 5: List of antibodies for flow cytometry...........................................................93
Table 6: List of antibodies for IFS............................................................................ 98
Table 7 Primer sequences..................................................................................... 101
VII
Abstract
Chronic inflammation and activation of angiogenesis sustain tumor progression. 
Recent data indicate that tumor-infiltrating myeloid cells support tumor 
angiogenesis by regulating multiple pro-angiogenic pathways. However, the 
functional heterogeneity of myeloid cells -  macrophages in particular -  may be 
greater than currently appreciated, and the relative contribution of distinct myeloid 
cell types to tumor angiogenesis is currently poorly known. Our laboratory 
identified a subset of tumor-associated macrophages (TAMs) that are required for 
tumor angiogenesis -  the Tie2-expressing macrophages (TEMs). TEMs appear 
pre-committed to a pro-angiogenic function already when they circulate as 
monocytes and their elimination from tumor-bearing mice blunts tumor 
angiogenesis without affecting the recruitment of other myeloid subsets to the 
tumors. Yet, both the molecular bases of TEMs pro-angiogenic activity and the 
functional role of the TIE2 receptor in TEM biology are currently unknown. To 
investigate the molecular identity of TEMs, I developed protocols to purify TEMs 
and TIE2- TAMs from tumors and compared the gene expression profile of these 
2 tumor macrophage subsets. I found that the TEM gene signature is consistent 
with enhanced pro-angiogenic and tissue-remodelling activity. From such 
analyses, novel surface markers were established that easily and unambiguously 
identify TEMs in tumors. Furthermore, I found that circulating Ly6C- monocytes 
and tumor-infiltrating TEMs express similar gene signatures, suggesting possible 
developmental relationships between the two myeloid subsets. TEMs, but not 
other tumor-infiltrating myeloid cells, express the angiopoietin receptor TIE2. To 
study the functional role of TIE2 in TEMs, I developed a novel lentiviral vector- 
based, conditional gene knock down platform. Remarkably, Tie2 knock-down in 
TEMs significantly inhibited angiogenesis and microvascular perfusion in a 
spontaneous tumor model, recapitulating several features of TEM elimination. In 
conclusion, these studies provided a molecular characterization of TEMs and 
related myeloid cells and identified TIE2 as a critical regulator of their 
proangiogenic function in tumors.
1
2
Introduction
1 Innate immunity: historical perspective
In 1908, Ilya Metchnikoff (1845-1916) and Paul 
Ehrlich (1854-1915) were jointly awarded the 
Nobel Prize in Physiology or Medicine, in 
recognition of their pioneering work on immunity 
(Mechnikov 1908; Ehrlich 1908). This event led 
to the birth of immunology as an academic 
discipline and the beginning of dichotomous 
thinking regarding innate and adaptive immunity.
Ilya Metchnikoff, the father of cellular immunity, 
described the phagocytic activity carried out by 
macrophages (Mcps) and neutrophils (which he 
called microphages). He reported that Mcps are 
present in different organs, and that 
phagocytosis is used not only for host nutritional 
activity and scavenging of degenerated and 
apoptotic cells (processes that he called 
physiological inflammation), but is also used 
during pathological inflammation, a host defence 
mechanism against invading pathogens (Chang
2009). Similarly, Paul Ehrlich is considered the 
father of the humoral theory of immunity. He hypothesized that living cells express 
side-chains that can recognize a particular toxin, like a key in a lock (Kaufmann 
2008). Ehrlich theorized that a cell under threat can express additional side-chains
Illustration 1: Paul Ehrlich (top) and 
Ilya Metchnikoff (bottom). Source: 
nobelprize.org
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to bind the toxin, and that these can be released from the cell surface to become 
the antibodies that are circulated through the body. It was these antibodies that 
Ehrlich first described as magic bullets in search of toxins. In the early 1900s, 
Ehrlich's magic bullets were used for the first time to treat established tumors 
using an immunotherapy strategy (Chang 2009).
Following Metchnikoff description of M(ps in Metazoans as early as 1892, cell 
types with similar features were reported thereafter. Under the name of 
clasmatocytes, Ranvier gave a histologic characterization of the Mcps in mammals; 
similar cells in the peritoneum were termed by Marschand adventitial cells. 
Maximow found these cells distributed in the connective tissue of mammals and 
termed them resting wandering cells. A similar type of cell was designated by Foot 
as endothelial phagocyte and by Kiyono as histiocyte. It is, therefore, apparent that 
all these terms refer to a similar cell type (Fry 1936).
1.1 Reticulo-endothelial system
Cells sharing a common origin, morphology, and function may be considered as 
belonging to a single entity and as constituting a "system". In 1924, Aschoff 
developed the "Mcp system" concept and, based on functional similarities, he 
grouped several kinds of cells in what he called the reticulo-endothelial system 
(RES) (van Furth et al. 1972). According to Aschoff, the properties which justify
Increase
of
phagocytic
activity
Endothelial cells 
Fibrocytes
Reticular cells of spleen and lymph nodes |  in
Reticuloendothelial cells of lymph and blood |
sinuses, including Kupffer cells j  5enss
Histiocytes
Sptenocytes and monocytes
RES in 
a wider 
sense
Illustration 2: The reticuloendothelial system (RES) of Aschoff (from van Furth et al. 1972)
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inclusion in the RES are best defined as a pre-eminent capacity for ingestion, 
concentration, and storage of foreign and autogenous substances of particulate 
nature, such as micro-organisms, cell debris and body fluids (Fry 1936). The cells 
discussed by Aschoff and ranked in increasing order of phagocytic activity are 
shown in Illustration 2.
The least phagocytic cells are endothelial cells (ECs), which form a thin layer of 
cells that line the interior surface of blood vessels, assembling a non-thrombogenic 
surface between circulating blood in the lumen and the rest of the vessel wall. 
Endothelial tissue is mesoderm-derived and is a specialized type of simple 
squamous epithelium. The presence of vimentin rather than keratin filaments 
allows to distinguish endothelial from epithelial cells.
More phagocytic than ECs are the fibrocytes and reticular cells. Fibrocytes and 
fibroblasts are believed to be two states of a same cell, the latter being the 
activated state. Similar to endothelium, fibrocytes are mesoderm derived and thus 
express vimentin. Fibroblasts produce glycoproteins and glycosaminoglycans, but 
also collagenous, reticular and elastic fibers, found in the extracellular matrix of 
connective tissue. Reticular fibers are composed of type III collagen and are 
produced also by reticular cells, but unlike fibroblasts, reticular cells retain reticular 
fibers intracellularly. This cellular scaffolding is called cytoreticulum, and allows the 
creation of non-fibrillar, wholly cellular stroma (found in thymus and spleen 
germinal centers, where T and B cells develop, respectively).
By far the most phagocytic cells are Mcps (histiocytes) and monocytes, which also 
originate from mesoderm, as do all hematopoietic cells (HCs). Both monocytes 
and Mcps play a central role in inflammation, which is a tightly regulated process 
initiated following tissue injury or infection. The main function of inflammation is to 
eliminate the pathogenic insult and to remove damaged tissue, with the aim of
5
restoring tissue homeostasis. The concerted action of several cell types— ECs, 
neutrophils, monocytes and Mcps — is crucial to the effective elimination of 
intruders and cell debris (Soehnlein & Lindbom 2010). Mouse models with 
genetically depleted Mcps provided functional evidence for the important trophic 
function of Mcps in tissue development and regeneration, namely in ductal 
branching, bone, Langerhans islets and renal development, neural networking, 
angiogenesis and the maintenance of reproductive function (Pollard 2009; 
Ovchinnikov 2008; De Palma et al. 2005).
1.2 Mononuclear phagocyte system
It is now established that there is no direct ontogenic relationship between all the 
cellular components of the RES, especially not between ECs and Mcps (Goerdt et 
al. 1996). For this reason, during a conference on mononuclear phagocytes (MP) 
held in Leiden, The Netherlands, in 1969, a new classification of these cells based 
on ontogeny was proposed for discussion. All highly phagocytic mononuclear cells 
and their precursors were grouped in the Mononuclear Phagocyte System 
(Illustration 3). The functional criteria initially adopted to justify the inclusion of a 
cell type in the MP system were:
1. phagocytosis mediated by immunoglobulins with or without complement 
(i.e. immune phagocytosis by "professional phagocytes", to distinguish them 
from "facultative phagocytic cells" such as fibroblasts, reticular cells, and 
ECs);
2. the ability to attach firmly to a glass surface;
3. belong to the mononuclear phagocyte lineage, i.e. to originate from a 
precursor cell in the bone marrow (BM), to be transported via the peripheral 
blood as monocyte, and eventually to become a tissue M(p (van Furth et al.
6
1972).
These criteria (van Furth et al. 1972), together with the knowledge available at the 
time, allowed the inclusion in the MP system of M(ps from many different organs
•Location'
MDP
CDP
co Ly6C+
monocyteLy6C-
monocyte PDCPre-cDC
Ly6C‘
monocyte
Ly6C+
monocyte PDCPreo
1 F1 r
onocMacrophage PDC
Illustration 3: The M P system in mice. Monocyte DCs progenitors (MDP) give rise to Ly6C+ 
monocytes, and to classical DCs progenitors (CDP). It remains to be shown whether MDPs give 
rise directly to Ly6C - monocytes (dotted line). Ly6C+ monocytes convert in the BM  to give rise to 
Ly6C - monocytes. The two monocyte subsets; Ly6C+ and Ly6C - egress from the BM and enter 
the peripheral circulation. Under steady state conditions, Ly6C - monocytes might contribute to 
the tissue M(p compartment. Ly6C+ monocytes can under inflammatory conditions give rise to 
Mcps and dendritic cells. CDPs give in the BM rise to pre-classical dendritic cells and 
plasmacytoid DCs (PDC). Pre-classical dendritic cells (Pre-cDC) circulate in blood and enter 
lymphoid tissue, where they give rise to classical DC. (from Yona & Jung 2010)
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(connective tissue, serous cavities, liver, lung, spleen, bone, brain) under both 
normal and pathological conditions. At the same time, fibroblasts, reticular and 
ECs were excluded. Of note, splenic and lymph node dendritic cells (DCs) were 
excluded from the MP system, mainly because it was believed that DCs do not 
originate from blood monocytes (van Furth et al. 1972). Interestingly, although it 
was recently confirmed that in homeostatic conditions splenic DCs develop from a 
BM progenitor without a monocytic intermediate (Varol et al. 2007), it is now 
accepted that DCs are MP specialized in antigen presentation to T cells (Hume et 
al. 2002).
Although neutrophils are professional phagocytes that can phagocytose opsonised 
bacteria, they are excluded from the MP system because they are not derived 
through a monocytic intermediate. The production and life cycle for MP is more 
complex than for neutrophils. MP of the blood and tissues survive far longer than 
neutrophils (a feature clinically important; patients suffer from a high risk of fatal 
infections following transient interruption of neutrophil production). Monocytes 
have a preserved capacity to augment production of granule proteins through new 
protein synthesis, a feature that is lost in mature neutrophils. Of historical interest 
in this regard, lnterleukin-1 (IL1) -  the endogenous pyrogen thought for many 
years to be primarily a product of neutrophils -  is now known to be predominantly 
produced by MP, because of their greater capacity for protein synthesis and 
cytokine production (Dale et al. 2008). At sites of acute inflammation, monocytes 
accumulate more slowly, but persist longer then neutrophils, which however play a 
central role during initial phase of inflammation (see paragraph 3).
In the last decade, the MP system framework has been further challenged by 
studies on monocyte transdifferentiation (Hume et al. 2002) and ontogeny of 
embryonic M(ps (see paragraph 1.2.a). There has been considerable controversy
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in the literature as to whether monocyte transdifferentiation in non-hematopoietic 
cell types is a significant mechanism in either normal homeostasis or tissue repair. 
At least in vitro, mature blood monocytes and inflammatory M(ps can apparently 
transform into vascular elements, including ECs, myofibroblasts and smooth 
muscle cells. The RES framework, which is based on functional similarities, would 
be more suited to explain these results. However, transdifferentiation is a very rare 
event, and the mechanism probably involves monocyte cell fusion, rather than true 
lineage change (Hume 2006; Wagers et al. 2002).
1.2.a Embryonic Mq>s and the mononuclear phagocyte system
The MP system is largely an ontological definition for vertebrates and is useful for 
classifying Mcps in adults. The embryo seems to contain a Mcp population that does 
not fit in the MP system framework. The primitive embryonic Mcps (peMcps) indeed 
seem to originate from monopotent precursors in the yolk sac mesoderm at 7.5 
days post coitum (dpc), before the development of definitive hematopoiesis. Thus, 
peMcps bypass the monocyte-like stage, and are observed in the yolk sac, and 
later on in the embryo starting at 8 dpc (Ovchinnikov 2008). Whether these peMcps 
persist and/or proliferate in adult tissues is not known. On the other hand, 
definitive embryonic Mcps (deMcps) form as part of the definitive hematopoiesis 
process (i.e. from myeloid precursors and through the monocyte stage) and thus 
share more properties in common with their counterparts found in the adult animal 
than the peMcps (Ovchinnikov 2008). Interestingly, Langerhans cells (LCs) were 
recently shown to develop from deMcps that colonize the epidermis before birth, 
differentiate in situ, and then proliferate during the first week of life to establish the 
LC network. Moreover, adult LCs self-renew in situ and can massively proliferate 
during inflammation (Chorro et al. 2009).
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1.3 Local proliferation of resident tissue mononuclear phagocytes
There is increasing evidence for resident tissue Mcps to be largely maintained 
through local proliferation under steady state conditions. This has been reported 
for Mcps as diverse as alveolar Mcps (Landsman & Jung 2007), the previously 
mentioned LCs (Chorro et al. 2009) as well as brain microglia (Ajami et al. 2007). 
On the other hand, there is evidence suggesting that in the absence of 
inflammation, local proliferation is negligible, if any, for splenic white-pulp and 
metallophilic Mcps (Wijffels et al. 1994) and liver kupffer cells (Crofton et al. 1978). 
However, the proliferation potential of the various MP subsets is largely unknown, 
in particular under inflammatory conditions.
1.4 Monocyte subsets
Almost 30 years ago, two discrete subsets of human blood monocytes were 
identified by morphology, antigen presenting capability and the differential 
expression of the surface markers CD16 and CD14 (Ziegler-Heitbrock et al. 1991; 
Shen et al. 1983). These data provided the first clues to a potential existence of 
differential physiological activities of monocyte subsets. Although the 
discrimination and function of these populations is still a matter of intense 
investigation and controversy (Ziegler-Heitbrock et al. 2010), monocyte 
heterogeneity is now regarded to be a general theme, conserved among 
mammals, with monocyte subsets having been reported in cows, pigs, rats, mice 
and humans (Yona & Jung 2010).
Phenotypic characterization in the mouse identified two discrete blood monocyte 
subsets (Illustration 3), according to their expression of Ly6C, GR1, CCR2, 
CD62L, CD43 and CX3CR1 (Geissmann et al. 2003; Palframan et al. 2001). 
Ly6C+ monocytes were initially referred to as inflammatory monocytes because
10
they give rise to M(ps and DCs in a variety of infectious models. Ly6C- monocytes, 
the most mysterious subset, were initially termed resident monocytes because of 
their longer half-life in vivo and their ability to home to both resting and inflamed 
tissues (Geissmann et al. 2003; Geissmann et al. 2010). Recently, it was reported 
that Ly6C+ blood monocytes shuttle efficiently in the absence of inflammation from 
the blood back to the BM (Varol et al. 2007), suggesting that this subset is not 
short lived as previously thought (Geissmann et al. 2003). Intriguingly, intravital 
microscopy revealed that Ly6C- monocytes exhibit long-range crawling on the 
luminal side of the vascular endothelium (Auffray et al. 2007), a feature that led 
these authors to term these cells as patrolling monocytes. Emerging evidence 
suggests that the two monocyte subsets exert distinct functions and have distinct 
fates in vivo (Nahrendorf et al. 2007; Landsman et al. 2007; Varol et al. 2009). 
Although monocytes have long been considered as a developmental intermediate 
between BM precursors and tissue Mcps, it is now clear that many DCs and tissue 
Mcps do not originate from monocytes at steady state, and that monocytes exert 
specific effector functions during inflammation.
Inflammation rapidly mobilizes monocytes from the BM (Serbina & Pamer 2006) 
and the subcapsular red pulp of the spleen, where a major monocyte reservoir 
exists in mice (Swirski et al. 2009). These splenic reservoir monocytes are 
indistinguishable from circulating blood monocytes and appear to be generated in 
the BM (like conventional blood monocytes), rather than locally in the spleen. 
Following injury, both splenic reservoir monocyte subsets are mobilized to the site 
of inflammation in an angiotensin-mediated, CCR2-independent manner (Swirski 
et al. 2009), whereas emigration of Ly6C+ monocytes from BM is CCR2- 
dependent (Serbina & Pamer 2006). However, it is not clear whether inflammation 
elicited monocytes integrate into the steady state resident MP network, functioning 
in an identical manner to resident cells.
1.5 Heterogeneity of mononuclear phagocytes
Over the past 10 years, the main, unresolved controversy inside the MP system 
field regards the heterogeneity versus plasticity issue (Gordon & Taylor 2005). 
Since the discovery of DCs (Steinman et al. 1974) and their inclusion in the MP 
system, distinguishing DCs from Mcps still leads to confusion and debate in the 
field. Several factors contributed to this confusion:
1. the use of non-specific cell surface markers (such as CD11c);
2. the adaptability and plasticity of Mcps to the micro-heterogeneity present in 
different tissue environments;
3. the wrong assumption that what is true for DCs in lymphoid organs is also 
true in non-lymphoid organs and what is true under homeostatic conditions 
is also relevant in inflammation (Geissmann et al. 2010).
Some authors proposed to identify DCs as cells with sufficient migration potential 
to reach draining lymph nodes or T-cell zones and Mcps as tissue resident, sessile, 
trophic cells (Geissmann et al. 2010; Yona & Jung 2010; Pollard 2009). On top of 
this, it has been suggested that the critical contribution of monocytes to the MP 
system lies in their ability to get rapidly mobilized (from BM and splenic reservoir) 
and reach through the circulation any site of the organism (Yona & Jung 2010), 
potentially with different kinetics (Nahrendorf et al. 2007; Hart et al. 2009).
Mcps and DCs may represent two extremes inside the MP system. A similar 
conceptual polarity stems from studies of Mcp activation during inflammation. It was 
initially found that Mcps from Th1 (C57B/6 and B10D2) and Th2 (BALB/c and 
DBA/2) mice respond in a qualitatively different manner to the same stimuli in vitro. 
This Mcp polarization paradigm was referred to as M1/M2, in analogy to the 
Th1/Th2 model (Mills et al. 2000). M1/M2 does not simply describe activated or 
deactivated Mcps, but cells expressing distinct metabolic programs. M1
12
corresponds to the IFNg-dependent, classical activation and M2 corresponds to 
IL4/IL13-dependent, altenative activation of Mcps (Gordon & Martinez 2010). Fully 
polarized M1 and M2 Mcps obtained in vitro are believed to be the extremes of a 
continuum of functional states present in vivo (Mantovani et al. 2002). Since the 
heterogeneity and complexity of MP in vivo (both under homeostatic and 
inflammatory conditions) is still largely unknown, Mcp polarization has long been 
attributed to the plasticity and versatility of these cells in response to exposure to 
different micro-environmental signals (Mantovani et al. 2002). However, it should 
be emphasised that the heterogeneity of the MP system is moderately 
recapitulated by in vitro models. Indeed, in vitro generated Mcps and DCs, albeit 
useful to study some aspect of cell biology of phagocytosis and antigen 
presentation, do not represent a model to study the specialized functions of the 
diverse MP subsets that are present in different tissues (Geissmann et al. 2010) 
and that participate in inflammatory responses and tissue regeneration processes 
in vivo (Soehnlein & Lindbom 2010). Monocyte heterogeneity may contribute, at 
least in part, to MP plasticity in vivo. For instance, Ly6C- and Ly6C+ monocytes 
appear to be committed to readily differentiate into M2-like and M1-like MP, 
respectively.
In conclusion, a technological improvement will be required to shed more light on 
the fate of monocyte subsets and on the process of antigen presentation in vivo 
(Cavanagh & Weninger 2008), both in health and disease. The MP field will greatly 
benefit from cell specific tracking studies that use genetically encoded fluorescent 
reporters and intravital microscopy.
1.6 Acute versus chronic inflammation
Neutrophils, monocytes and M<ps are phagocytic cells that cooperate during the 
onset, progression and resolution of inflammation (Soehnlein & Lindbom 2010). In
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the first step, molecular alarm signals generated in response to sterile tissue 
damage and/or microbial invasion are recognized by resident MP (Rock et al. 
2010; Medzhitov 2007). Owing to their strategic location in close proximity to the 
site of injury, tissue-resident cells are the primary inducers of an inflammatory 
reaction. Patrolling monocytes have been proposed to take part to this phase also 
(Auffray et al. 2007). Following the recognition of danger signals, these tissue- 
resident cells synthesize leukotriene B4 (a strong secretagogue of neutrophil 
granule proteins and a powerful inducer of reactive oxygen species production) 
and chemokines, namely CXCL1, CXCL2, TNF and IL6 (phase I). During 
extravasation, neutrophils sequentially release preformed granules, which 
sensitize neutrophils to signals present in the milieu, induce ECs activation and 
permeability and promote Ly6C+ monocytes recruitment (phase II) (Soehnlein et 
al. 2008). Although the recruitment cascade for neutrophils and monocytes is 
similar, the two cell populations differ in their use of cell adhesion molecules and 
chemokines (Ley et al. 2007). After the inflammatory stimulus (e.g. pathogens) has 
been eliminated by the concerted action of neutrophils and MP, to avoid excessive 
tissue damage the healing process is actively triggered. Several mechanisms have 
a role in turning off neutrophil infiltration and promoting the uptake and clearance 
of apoptotic cells: 1) lipid mediator class switch (Serhan et al. 2008; Ravichandran 
& Lorenz 2007); 2) inhibition of neutrophil infiltration (Bournazou et al. 2009; 
Perretti & DAcquisto 2009); 3) chemokine inactivation (Soehnlein & Lindbom
2010); 4) down-regulation of granulopoiesis (Stark et al. 2005). Thus, inflammation 
is a self-limiting process, but under certain circumstances, failure in the resolution 
of inflammation hampers the restoration of tissue homeostasis and chronic 
inflammation ensues. Only recently, the mechanisms involved in this pathological 
diversion of the inflammatory response have started to be investigated. For 
instance, it has been proposed that if an adaptive immune response is activated
14
by persistent stimulation (longer than 7 days), a chronic inflammatory loop may 
establish when even adaptive immune responses (which involve T and B cell 
functions) fail to eradicate the stimulus. In such a scenario, the composition of the 
infiltrating leukocytes changes from neutrophils to a mixture of mononuclear 
phagocytes and T cells. Concomitantly, the inflammatory stimulus changes from 
the one sensed by pattern-recognition receptors of innate immune cells to the one 
recognized as an antigen by activating receptors on T and B cells of the adaptive 
immune system. Antigen-activated T cells can enhance effector functions of MP 
and neutrophils (for instance increasing the specificity of action by antibody 
mediated targeting) or recruit alternative effector cells, such as eosinophils. The 
specialized effector cells of adaptive immunity often succeed in eradicating a 
stimulus that resists clearance by innate immunity, which allows for resolution and 
repair. Prolonged antigenic stimulation by resistant microbes or tissue-derived 
auto-antigens leads to chronic inflammation with formation of an inflammatory neo­
tissue (Pober & Sessa 2007), which can eventually evolve to malignancy (de 
Visser et al. 2005).
2 Inflammation, angiogenesis and cancer
2.1 The hallmarks of cancer
Several lines of evidence indicate that tumorigenesis in humans is a multistep 
process and that these steps reflect genetic alterations that drive the progressive 
transformation of normal human cells into highly malignant derivatives. Taken 
together, observations of human cancers and animal models argue that tumor 
development proceeds via a process formally analogous to Darwinian evolution, in 
which a succession of genetic changes, each conferring one or another type of 
growth advantage, leads to the progressive conversion of normal human cells into
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cancer cells. The vast catalog of cancer cell genotypes is believed to be a 
manifestation of six essential alterations in cell physiology that collectively dictate 
malignant growth (Illustration 4). These six capabilities are shared in common by 
most and perhaps all types of human tumors (Hanahan & Weinberg 2000).
Whereas acquired
capabilities such as evading 
apoptosis, insensitivity to 
anti-growth signals and 
limitless replicative potential 
are clearly cell autonomous 
(Hanahan & Weinberg 
2000), the remaining three, 
i.e. self-sufficiency in growth 
signals, tissue invasion and 
metastasis and sustained 
angiogenesis can receive a 
direct, variable contributions 
from the micro-environment, 
Pollard 2010). Although it has 
been proposed that inflammation represents the 7th hallmark of cancer (Mantovani 
2009), angiogenesis is intimately linked to chronic inflammation and can account 
for it.
2.2 Tumor angiogenesis
Angiogenesis, a physiological process involving the growth of new blood vessels 
from pre-existing ones, is universally recognized as a hallmark of cancer (see 
paragraph 2.1). Angiogenesis is an obligate and rate-limiting factor for tumor
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Hanahan & Folkman 1996)
growth (Folkman et al. 2000). Indeed, the oxygen and nutrients supplied by the 
vasculature are crucial for cell function and survival, obligating virtually all cells in a 
tissue to reside within 100 pm of a capillary blood vessel. Because of this 
dependence on nearby capillaries, and since proliferating cells within a tissue do 
not have an intrinsic ability to stimulate blood vessel growth, incipient neoplasias 
must develop angiogenic ability in order to progress to a larger size (Hanahan & 
Weinberg 2000). According to the balance hypothesis (Hanahan & Folkman 1996), 
the switch to the angiogenic phenotype involves a change in the local equilibrium 
between positive and negative regulators of angiogenesis (Illustration 5). The 
ability to induce and sustain angiogenesis seems to be acquired in a discrete step 
during tumor development, in pre-neoplastic lesions, prior to the appearance of 
full-blown tumors (Hanahan & Folkman 1996).
2.3 Inflammation and cancer
Back in 1863, Rudolph Virchow documented the association between the 
lymphoreticular infiltrate present at chronically inflamed tissues and the site of 
origin of human cancer (Plytycz & Seljelid 2003). Such an observation was
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resurrected in recent years with the popular concept that inflammation and cancer 
are causally linked (Balkwill & Mantovani 2001). This concept is based both on 
epidemiological data linking chronic inflammation to a higher cancer risk and 
experimental evidence that certain inflammatory cells, such as TAMs, may 
facilitate tumor development (Mantovani & Sica 2010). It has been estimated that 
a significant proportion of chronic inflammatory diseases (such as inflammatory 
bowel desease, gastric ulcer, hepatitis) progress to cancer in predisposed patients 
(Coussens & Werb 2002). Chronic inflammation can cause initiating mutations in 
susceptible cell populations just like chemical carcinogens do. MP and neutrophils 
can induce DNA damage in proliferating cells, through their generation of reactive 
oxygen and nitrogen species that are produced normally by these cells to fight 
infection (Maeda & Akaike 1998). These species react to form peroxynitrite, a 
mutagenic agent. Hence, repeated tissue 
damage and multiple cycles of tissue 
regeneration of tissue (Illustration 6), in the 
presence of highly reactive nitrogen and 
oxygen species released from inflammatory 
cells, may accelerate the accumulation of 
genetic and epigenetic alterations that affect 
the expression or function of proto­
oncogenes and tumour suppressor genes in 
somatic cells (Hussain et al. 2003).
In 1880, seventeen years after Virchow's 
association between cancer and 
inflammation, Julius Cohnheim was the first 
to state that there is no inflammation without 
blood vessels (Doerr 1985). In non-inflamed
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tissues, vascular ECs maintain blood fluidity, regulate blood flow, control vessel 
wall permeability and keep circulating leukocytes quiescent. The activation of ECs 
involves rapidly acting, pre-synthesized and stored molecules (type I activation), in 
addition to a subsequently slower transcriptionally regulated response program 
(type II activation) (Pober & Cotran 1990). The angiopoietin-Tie2 system is 
emerging as a key regulator of EC homeostasis and activation. Angiopoietin-2, 
one of the two main Tie2 ligands, functions as an immediate autocrine switch of 
vascular responsiveness to exogenous stimuli and angiogenesis (see paragraph 
4.2) (Fiedler & Augustin 2006). Activated ECs trigger neutrophil recruitment 
(Fiedler et al. 2006), and thus play a central role in the first phase of inflammation 
(see paragraph 1.6). Thus, ECs activation is not only prerequisite for initiating 
angiogenesis, but also for triggering inflammation and inflammation-associated 
diseases (Illustration 6).
3 Myeloid cells and tumor angiogenesis
Oncogene activation and/or tumour suppressor gene inactivation can alter the 
expression of angiogenesis activators and inhibitors in transformed cells. However, 
these events may not be sufficient to trigger the angiogenic switch. In this regard, 
there is a growing interest in understanding the complex interactions between BM- 
derived myeloid-lineage cells and angiogenesis in tumors. Such interest has been 
revived recently by the observation that tumor-infiltrating myeloid cells convey pro- 
angiogenic programs that can counteract the activity of anti-angiogenic drugs in 
mouse tumor models (Shojaei & Ferrara 2008). Several studies highlighted the 
importance of BM-derived HCs in tumour angiogenesis (Bergers et al. 2000; 
Coussens et al. 2000; De Palma et al. 2003). HC subsets that have been directly 
implicated in tumour angiogenesis include mast cells (Coussens et al. 1999), 
TAMs (Lin et al. 2001), Tie2-expressing macrophages (TEMs) (De Palma et al.
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2003) and Gr1+ CD11b+ myeloid derived suppressor cells (MDSCs) (Yang et al. 
2004a). Other HCs types, such as platelets, neutrophils, DCs, eosinophils and 
hematopoietic progenitors may also participate in the angiogenic process, but it 
remains to be established whether they directly promote angiogenesis, rather than 
having a function in supporting tissue inflammation and remodelling (De Palma & 
Naldini 2006). However, the relative contribution of each of the aforementioned 
myeloid cell types to tumor angiogenesis has been limited so far by our little 
understanding of their developmental, phenotypic and functional identity in the 
context of the tumor micro-environment.
3.1 Monocytes/Macrophages
These cells are released from the bone marrow as pro-monocytes, mature into 
monocytes in the circulation, infiltrate tumors, and differentiate further into TAMs 
(Mantovani et al. 2008; Lewis & Pollard 2006). Once in tumors, M(ps express a 
wide array of pro-angiogenic factors, including vascular endothelial growth factor 
(VEGF)-A and matrix metalloproteinase (MMP)-9 (Coussens et al. 2000; Giraudo 
et al. 2004; Lewis et al. 2000). Evidence for their role in tumor angiogenesis has 
been established by several different experimental approaches. By using MMTV- 
PyMT mammary tumor-prone mice carrying a colony stimulating factor-1 (Csf1) 
null mutation (Csf10P/0P), Lin and co-workers (Lin et al. 2001; Lin et al. 2006) 
demonstrated that the absence of CSF-1 markedly decreased Mcp infiltration in 
pre-malignant tumors, and this, in turn, resulted in inhibition of tumor angiogenesis 
and delayed metastasis. Furthermore, inhibition of tumor-derived TAM 
chemoattractants, ablation of TAMs by DNA vaccination, or pharmacological 
neutralization of TAM-produced pro-angiogenic molecules also impaired tumor 
angiogenesis in various tumor models (Fischer et al. 2007; Luo et al. 2006; 
Giraudo et al. 2004). It should be noted, however, that in Ccr2-deficient, K14-HPV
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cervical tumor-prone mice, the genetic depletion of TAMs unleashed a 
compensatory neutrophil response that rescued tumor angiogenesis and 
progression (Pahler et al. 2008). This interesting observation highlights a certain 
degree of functional redundancy among tumor-infiltrating Mcps and neutrophils, 
that may vary in a tissue- or organ-specific fashion.
TAM depletion from tumors removes all of the many aspects of Mcp involvement in 
tumor progression. These include, in addition to the production of VEGF-A and 
other pro-angiogenic factors, the release of cellular mediators that promote 
immuno-suppression and enhance tumor cell survival, migration and invasion 
(Mantovani et al. 2008; Lewis & Pollard 2006; Condeelis & Pollard 2006). To 
specifically analyse the role of myeloid cell-derived VEGF-A in tumor 
angiogenesis, Stockmann and co-workers (Stockmann et al. 2008) crossed mice 
carrying /oxP-flanked Vegfa alleles to mice carrying a lysozyme M promoter-driven 
Cre recombinase. Interestingly, the authors found that the targeted deletion of 
VEGF-A in myeloid cells failed to inhibit angiogenesis and tumor growth or 
decrease the overall amount of VEGF-A expressed in tumors. Rather, it attenuated 
the vascular abnormalities commonly observed in tumors and improved tumor 
perfusion (a phenomenon previously referred to as "vascular normalization” (Jain 
2005)). These results suggest that VEGF-A production by TAMs promotes the 
formation of chaotic, poorly functional tumor-associated vasculature -  at least in 
the murine tumor models used.
It is rapidly emerging that TAMs may comprise distinct M(p subsets (Coffelt et al. 
2010a; Qian & Pollard 2010). Egeblad and co-workers(Egeblad et al. 2008) 
developed and applied multicolor imaging techniques (Hoffman & Yang 2006) to 
analyze the recruitment and behavior of M(ps and related myeloid cells in different 
tumor microenvironments in live mice. MMTV-PyMT mice were crossed with a
21
transgenic mouse line expressing GFP under the control of the promoter of the 
Csflr gene, which is specifically expressed in monocyte/Mcp-lineage cells. The 
movement of GFP+ cells within tumors was then visualized along with 
fluorescently labeled dextran (to label blood vessels and Mcps that endocytose 
dextran) and fluorescently labeled monoclonal antibodies (to better identify the 
myeloid cell subsets involved). Based on their motility, expression of surface 
markers (such as mannose receptor, MRC1/CD206) and ability to phagocytose 
dextran, the Mcps could be classified into distinct sub-populations, including low- 
migratory MRC1+ dextran+ Mcps found in the peri-tumor areas and sessile MRC1- 
dextran- Mcps found within the tumor mass (Egeblad et al. 2008). This real-time 
analysis of myeloid cell location, behavior and gene expression within intact, live 
tumors, showed that the functional heterogeneity of tumor-infiltrating myeloid cells 
-  Mcps in particular -  may be greater than anticipated by the analysis of static 
markers on fixed tissues. As of today, at least four distinct TAM subsets have been 
identified and profiled from tumors (Qian & Pollard 2010; Pucci et al. 2009)
Monocytes are highly plastic cells and it is generally believed that their intra- 
tumoral differentiation toward distinct Mcp subsets is regulated by the contextual 
assortment of cytokines, chemokines and growth factors present in the tumor 
microenvironment. For instance, IL-4, IL-13 and IL-10 are thought to directly 
stimulate the growth-promoting and pro-angiogenic functions of TAMs, a process 
known as alternative Mcp activation or M2 polarization (Mantovani et al. 2002) (see 
paragraph 1.5 on page 12). However, it is also possible that distinct monocyte 
subsets give rise to distinct Mcp sub-populations in tumors (Pucci et al. 2009). 
Whether the different monocyte/Mcp subsets found in tumors (Coffelt et al. 2010a; 
Qian & Pollard 2010) represent distinct lineages (Pucci et al. 2009) or more plastic 
differentiation states (Mantovani et al. 2002), and whether they are related to each 
other by a precursor-to-mature cell relationship, is the object of current
22
investigations.
3.2 Polymorphonuclear phagocytes
Granulocytes, neutrophils in particular, and mast cells are regarded as a key 
source of pro-angiogenic factors in certain experimental tumors. An early study 
examining the importance of MMP9 and VEGF-A in pancreatic tumors of RIP1- 
Tag2 mice noted that inflammatory cells are the main producers of these two pro- 
angiogenic molecules in tumors (Bergers et al. 2000). Neutrophils, together with 
monocytes/M(ps, have since been identified as the predominant source of MMP9 
and other pro-angiogenic molecules in RIP1-Tag2 mice (Nozawa et al. 2006; 
Shojaei et al. 2008). Although neutrophils are found in lower frequency than Mcps 
in RIP1-Tag2 insulinomas, their elimination by means of anti-GR1 antibodies 
(which, however, also bind Ly6C+ inflammatory monocytes; see paragraph 1.4 on 
page 10) in this tumor model reduces the levels of MMP9 in the tumors, which in 
turn inhibits the association of VEGF with VEGF receptor-2 (VEGFR-2) on ECs, 
thus suppressing angiogenesis.
MDSCs are a heterogeneous population of myeloid cells that encompasses 
immature monocytes, granulocytes, DCs and their precursors. The defining 
characteristics of MDSCs are largely based on their ability to suppress innate and 
adaptive immunity and expression of CD11b and GR1 (Gabrilovich & Nagaraj 
2009; Capuano et al. 2009), whereas expression of other phenotypic markers by 
MDSCs varies due to their diversity and inclusion of myeloid cells at various 
stages of differentiation. Recent attempts at narrowing down specific subsets of 
these cells conclude that this group of ceils can be divided into monocytic 
(mononuclear-MDSCs) and neutrophilic (polymorphonuclear-MDSCs) and DC 
subsets, which express phenotypic markers characteristic of each respective 
subset (Umemura et al. 2008; Youn et al. 2008). There is also some evidence
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indicating that these subsets may have different functions in tumors (Movahedi et 
al. 2008), but the predominant phenotype and differentiation status of these cells 
once they migrate into premalignant tissue and tumors is unclear and is likely 
dependent on the tumor model and tumor type. While MDSCs are believed to 
promote tumor progression through immunosuppression and other mechanisms, 
these cells (or subsets of them, such as neutrophils) may also influence 
angiogenesis (Shojaei et al. 2007; Yang et al. 2004b) an effect mediated, at least 
in part, by their release of pro-angiogenic factors. In this regard, Shojaei and co­
workers (Shojaei et al. 2007) found that tumor refractoriness to anti-VEGF therapy 
correlates with the marked accumulation of CD11b+ GR1+ myeloid cells within 
certain mouse tumors. This finding suggests that some tumors may co-opt VEGF- 
independent, pro-angiogenic programs that are executed by the tumor-infiltrating 
myeloid cells. Yet, an immuno-suppressive function has not been conclusively 
demonstrated for the pro-angiogenic CD11b+ GR1+ cells, raising the question of 
whether or not they can truly be referred to as MDSCs.
A number of experimental animal models have shown mast cells to be important 
for tumor angiogenesis (Criveilato et al. 2008). Mast cells accumulate during the 
pre-malignant stages of tumor progression and at the periphery of invasive tumors. 
They have direct pro-angiogenic activity due to their production of MMPs, 
particularly MMP-9, and secretion of other pro-angiogenic molecules such as basic 
fibroblast growth factor (FGF), VEGF, and IL-8. In addition, mast cells indirectly 
stimulate angiogenesis by secreting mast cell-specific serine proteases that 
activate pro-MMPs and stimulate stromal fibroblasts to synthesize collagens (De 
Palma & Coussens 2008). Tumors grown in transgenic mice deficient in mast cells 
exhibit delayed tumor vascularization and progression. For instance, premalignant 
angiogenesis is abated in a mast cell-deficient, skin tumor-prone K14-HPV 
transgenic mouse (Coussens et al. 1999), as well as during pancreatic islet cell
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carcinogenesis (Soucek et al. 2007), melanoma progression (Starkey et al. 1988), 
and adenomatous colon polyposis (Gounaris et al. 2007).
In conclusion, the promiscuous cell markers routinely used to identify myeloid cells 
in tumors, together with the limited availability of mouse models and experimental 
tools that allow dissecting the contribution of each of the distinct myeloid cell types 
potentially involved, have confounded the interpretation of the role of myeloid cells 
in tumor angiogenesis. High-resolution, single-cell live imaging analysis of tumor- 
infiltrating myeloid cells is unraveling an unexpected degree of functional 
heterogeneity (Egeblad et al. 2008). Whereas further studies will likely establish 
the developmental and functional overlap of some of the aforementioned pro- 
angiogenic myeloid cell types, it is increasingly appreciated that TAMs comprise 
functionally and perhaps developmentally distinct subsets.
3.3 TIE2-expressing macrophages (TEMs)
While the origin and growth pattern of tumor cells differ enormously from tumor to 
tumor, angiogenesis involves genetically stable host tissues and follows recurrent 
patterns. Moreover, angiogenesis occurs under few physiological conditions of 
adult individuals and angiogenic vessels display different features from those of 
established blood vessels. Indeed, it is well known that tumor vessels appear 
structurally immature, exhibit poor association between ECs and supporting cells 
and are often leaky and haemorrhagic (Hashizume et al. 2000). In addition, ECs of 
tumor vessels display distinctive protein expression profiles, such as the specific 
expression or the up-regulation of matrix proteases, adhesion molecules and 
receptor tyrosine kinases (St Croix et al. 2000). For these reasons, newly forming 
tumour vessels have long been regarded as a target that could be exploited for the 
delivery of cancer therapeutics (Folkman 1971).
To specifically target exogenous genes to tumor angiogenesis, De Palma et al.
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generated lentiviral vectors (LVs) with EC-specific expression (De Palma et al.
2003). LVs containing promoter and enhancer sequences from the mouse Tie2 
gene (Tie2p/e) proved to be the most EC-specific in vitro. Direct injection of 
Tie2p/e-GFP LVs into mammary tumor allografts resulted in targeted and efficient 
expression of the Tie2p/e vector in tumor ECs. Unexpectedly, the Tie2p/e vector 
also targeted gene expression to a subset of stromal cells expressing the pan­
leukocyte marker CD45 and mostly localized at the tumor periphery (De Palma et 
al. 2003). The transplant of BM cells transduced ex vivo with Tie2p/e-GFP LVs into 
irradiated mice showed that only a small fraction of blood leukocytes and marrow 
cells are weakly Tie2p/e-GFP+. The circulating Tie2p/e-GFP+ cells are myeloid- 
lineage (CD45+, CD11b+, CD19-) cells, and were initially termed Tie2-expressing 
mononuclear cells (TEMs) (De Palma et al. 2003). Once recruited to the tumors, 
TEMs express a CD45+ CD31- CD11b+ F4/80+ phenotype and mostly localize at 
the tumor periphery and/or associate with small blood vessels dispersed within the 
tumor parenchyma (Illustration 7). Remarkably, GFP expression is detected only in 
tumors but not in non-angiogenic organs such as spleen, lung, liver, heart or brain. 
However, TEMs are also recruited to sites of non-tumor angiogenesis, namely in 
the granulation tissue surrounding regenerating hepatic lobules following 
hepatectomy and during wound healing. Of note, the Tie2p/e LVs is very weak in 
leukocytes, indicating minimal expression of TIE2 in the circulating monocytes. 
Thus, alternate surface markers that easily and unambiguously identify TEMs are 
highly desired.
At the time of these studies (De Palma et al. 2003), a new concept in the field of 
tumor biology was emerging. BM derived endothelial progenitor cells (EPCs) were 
reported to contribute substantially to tumor vessels by vasculogenesis, the 
process of de novo formation of blood vessels from angioblast-like EPCs (Lyden et 
al. 2001). Although TEMs do not incorporate into newly formed tumor vessels, they
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Illustration 7: TEMs in a tumor section. Immunofluorescence staining of a tumor 
section from a Tie2p/e-GFP BM chimera mouse. O f note, the perivascular 
position of Tie2p/e-GFP+ TEMs, which contrast to the widespread distribution of 
CD11b+ myeloid cells (in blue). Blood vessels are in red. De Palma et al. 2008.
share several surface markers with ECs, TIE2 in primis (Prater et al. 2007; De 
Palma & Naldini 2006). This, together with the close proximity between tumor ECs 
and TEMs, may have erroneously led several authors to regard TEMs as BM- 
derived ECs, i.e. EPCs. Thus, to study TEM biology, the choice of markers 
employed to identify them is of paramount importance.
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3.3.a TEMs are pre-committed to a angiogenic function
The peculiar peri-vascular localization of TEMs suggests a potential role in the 
regulation of tumor angiogenesis. Indeed, conditional TEM depletion by employing 
the Tymidine Kinase (TK) suicide gene abates the recruitment of TEMs to the 
developing tumors and markedly inhibits tumor angiogenesis (De Palma et al.
2005). Interestingly, TEM elimination does not affect the overall number of TAMs 
and granulocytes, making it unlikely that TEMs comprise precursors of TAMs 
(Illustration 8). Rather, these studies suggest that TEMs represent a distinct TAM
-  g c v  + GCV
Illustration 8: TEM depletion experiment. Tumor-bearing Tie2p/e-TK-GFP BM 
chimera mice were treated (right panels) or not (left panels) with Gancyclovir (GCV) 
in order to deplete TEMs. Of note, after virtually complete TEM depletion, the 
presence of tumor-infiltrating CD11b+ myeloid cells is not affected. De Palma et al. 
2005.
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subset with inherent, non-redundant pro-angiogenic activity. TEMs hold this pro- 
angiogenic activity already when they circulate in the peripheral blood, before 
reaching the tumour site (De Palma et al. 2005). Recent data confirmed that 
human TEMs, similar to their murine counterpart, are already pre-committed to a 
pro-angiogenic function in the circulation (Coffelt et al. 2010b). Thus, TEMs are a 
pre-committed MP subset with innate pro-angiogenic activity. In this regard, the 
identification of pro-angiogenic TEMs among the heterogeneous TAM population 
challenges the notion that transition of tumour Mcp phenotype between growth- 
inhibitory and growth-promoting activity is exclusively and contextually modulated 
by the tumour micro-environment (Mantovani et al. 2002). Nevertheless, the 
molecular bases of the pro-angiogenic activity of TEMs and the role of TIE2 in 
TEM biology need to be elucidated.
Regarding putative TEM precursors, it has been reported that TIE2 is expressed 
by long term repopulating hematopoietic stem cells (HSC) and mediates their 
quiescence in the BM niche (Arai et al. 2004). This may explain why TK-based 
TEM depletion did not cause obvious myelotoxicity in mice, as this conditional Cell 
elimination system only kills proliferating cells (De Palma et al. 2005). However, 
the BM progenitor/precursor of circulating and tumor-infiltrating TEMs remains to 
be identified.
3.3.b Exploiting TEMs to deliver therapeutics to tumors
Based on the unique tumor-homing specificity of TEMs among myeloid-lineage 
cells and the selective expression of the Tie2 gene in TEMs among the progeny of 
BM-derived HSCs, our laboratory explored the possibility of targeting an anti-tumor 
cytokine (i.e. IFNa) to tumors by exogenously expressing it in TEMs (De Palma et 
al. 2008). Whereas HSCs constitutively expressing IFNa failed to engraft, Tie2p/e- 
IFNa transduced HSCs were able to successfully reconstitute mice long-term.
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Although IFNa was not detectable in the plasma of Tie2p/e-IFNa mice, when 
challenged orthotopically with human glioma cells, these mice were resistant to 
tumor growth. Interestingly, by exploiting the species difference between the tumor 
and the host (human and mouse, respectively), we were able to show that the 
IFNa response of host-derived components of the tumor is sufficient to inhibit 
human glioma growth (De Palma et al. 2008).
In mice developing spontaneous metastatic mammary tumors (MMTV-PyMT), 
TEM mediated delivery of IFNa substantially (50%) reduced tumor volume. Tumor 
specific activation of type I IFN inducible genes was the molecular evidence for the 
selective targeting of the IFN response to mammary tumors but not to other 
organs. TEM-mediated IFNa delivery enhanced the recruitment and promoted the 
activation of both innate and adaptive immune cells. Finally, effective metastasis 
suppression in Tie2p/e-IFNa BMT mice was observed (De Palma et al. 2008).
In summary, TEM-mediated delivery of bioactive peptides is a safe, specific and 
effective way to contrast tumor growth and metastasis. Of note, the tumor 
microenvironment, if properly elicited, is able to reject the tumor.
3.3.c Human TEMs
Recently, our and other laboratories reported the existence of TEMs in human 
blood and cancer (Murdoch et al. 2007; Venneri et al. 2007; Pulaski et al. 2009; 
Coffelt et al. 2010b). In human cancer specimens, TEMs are a minor proportion of 
the bulk of tumor-infiltrating leukocytes -  which mostly comprise TAMs and 
granulocytes. TEMs are found both in peri-vascular and avascular viable (hypoxic) 
areas of human tumors and are largely missing in non-neoplastic tissues adjacent 
to tumors. In addition to tumors, TEMs can be detected at low frequency in the 
human peripheral blood (Venneri et al. 2007; Murdoch et al. 2007; Coffelt et al. 
2010b). Similar to murine cells, human TEMs isolated from peripheral blood also
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have pro-angiogenic activity (Venneri et al. 2007; Coffelt et al. 2010b). Lewis and 
co-workers showed that circulating human TEMs are already pre-programmed in 
the circulation to be more pro-angiogenic than TIE2- monocytes. Additionally, 
angiopoietin-2 markedly enhanced the pro-angiogenic activity of human TEMs by 
up-regulating their expression of the pro-angiogenic gene thymidine 
phosphorylase.
4 TIE2 receptor
In the mouse and human system, the 
TIE2 receptor is almost exclusively 
expressed by ECs, HSCs and TEMs.
The Tek gene encodes for the TIE2 
protein. TIE2 is a receptor tyrosine 
kinase which possesses a unique
extracellular domain containing 3 
immunoglobulin-like loops which fold 
together with 3 epidermal growth
factor-like repeats and three fibronectin type III repeats (Illustration 9) (Barton et al.
2006). Studies with dominant-negative and null mice reveal that loss of Tie2 gene 
function results in embryonic death at 9.5 dpc as a consequence of an
underdeveloped vasculature (Sato et al. 1995; Dumont et al. 1994). TIE2 is
expressed at high levels in blood and lymphatic ECs, whereas HSCs and tumor- 
infiltrating TEMs express much lower levels (up to 100-fold less).
4.1 Signalling mechanism
Initially described as an orphan receptor (Dumont et al. 1992), TIE2 was 
subsequently shown to interact with all four of the angiopoietins (ANG1 -  ANG4)
Illustration 9: Schematic 
representation of the 
EGF2 domain organization of
EGF3 ^  the TIE receptors. (From
Barton et al. 2006)
FNIll ^
Kinase*
Tis2
(Valenzuela et al. 1999). The different angiopoietins, although having high 
sequence homology, elicit different responses from the TIE2 receptor. Indeed, 
ANG1 is a constitutive receptor agonist, while ANG2 is a context-dependent one 
(Ward & Dumont 2002). The four known angiopoietins each contain an N terminus 
that modulates angiopoietin clustering and a C terminus that mediates the 
interaction with TIE2 (Davis et al. 2003). Ligand oligomerization is necessary for 
receptor activation. Indeed, all angiopoietins exist primarily as tetramers, 
hexamers and higher order oligomers in solution (Ward & Dumont 2002; Seegar et 
al. 2010). Ligand-induced oligomerization of the extracellular regions of TIE2 leads 
to activation of the intracellular tyrosine kinase domain, which creates binding sites 
for Src homology 2 and phosphotyrosine binding domain containing proteins 
(Lemmon & Schlessinger 2010).
TIE1, although a close homolog of TIE2, does not interact directly with the 
angiopoietins, and its in vivo ligands are yet to be identified. A recent study using 
catalytically inactive TIE2 demonstrated that TIE1 phosphorylation is dependent on 
a functional TIE2 (Yuan et al. 2007). Recently, it has been proposed that TIE1 is 
an inhibitory co-receptor. Specifically, in cells expressing both TIE1 and TIE2, the 
receptors form heterodimers that inhibit Tie2 activation and clustering. Binding of 
ANG1 to TIE2 promotes heterodimer dissociation, TIE2 clustering, and signalling 
initiation. On the other hand, ANG2 is unable to dissociate the inhibitory TIE2-TIE1 
complexes upon binding TIE2 and, therefore, does not induce TIE2 clustering and 
signaling, yet behaves as a competitive antagonist by blocking further binding of 
ANG1. Indeed, both ANG1 and ANG2 bind to the same region of Tie2 (Barton et 
al. 2006). Alternatively, in cells that do not express TIE1, all angiopoietins promote 
TIE2 clustering and activation (Seegar et al. 2010). This model proposes that the 
balance of TIE1 and TIE2 expression modulates the functional potential of ANG2, 
and by analogy, vascular homeostasis. However, this model is based on studies
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Illustration 10: Model for Angiopoietin-Mediated TIE2 Signaling. Left: expression of TIE2 in the 
absence of TIE1 at sites of vessel quiescence and maturity. In the absence of TIE1, TIE2 can be 
activated with either ANG1 orANG 2. Both ligands stimulate receptor clustering, tyrosine kinase 
activity, and downstream signaling events, effectively become unresponsive to vessel sprouting 
and branching cues. Middle and right: within sites of active angiogenesis, TIE1 and TIE2 
associate to form a complex prior to ligand stimulation. Upon addition ofA N G 2 (right), TIE1 and 
TIE2 association and localization remain unchanged. Under these conditions, ANG 2 fails to 
activate the TIE2 receptor and opposes the activation of downstream signaling generated by 
ANG1. However, upon addition of ANG1 (middle), the opposite is observed. ANG1 stimulates 
TIE2 clustering, tyrosine kinase activity, and downstream signaling events similar to those 
observed in the absence of Tie1. Angiopoietins are depicted as dimers for illustration purposes, 
although they are known to exist as higher-order clusters, (from Seegar et al. 2010)
performed in ECs and it is not known if it holds true also in HCs.
33
4.2 Regulation of vascular homeostasis
ANG1 is constitutively expressed by many different cell types such as pericytes, 
smooth muscle cells and fibroblasts (Sundberg et al. 2002). Constitutive ANG1 
expression and low level TIE2 phosphorylation in the adult vasculature suggest 
that ANG1-mediated TIE2 signaling functions as the default pathway to control 
vascular quiescence. ANG1 exerts a protective effect on the endothelium, limits its 
ability to be activated by exogenous cytokines and growth factors and inhibits 
vascular leakage. For these reasons, it has an anti-inflammatory action.
On the other hand, ANG2 is almost exclusively expressed by ECs (Fiedler et al.
2004). Angpt2 mRNA is almost undetectable in the quiescent vasculature and 
dramatically upregulated in tumor blood vessels (Stratmann et al. 1998). ANG2 
expression is regulated by several different cytokines (FGF2, VEGFs and TNF) 
and environmental cues (hypoxia, high glucose levels and superoxides) (Fiedler & 
Augustin 2006). ANG2 protein is stored in EC Weibel-Palade bodies and thus is 
readily available following endothelial stimulation. The release of ANG2 results in 
rapid destabilization of the endothelium, suggesting that ANG2 functions as an 
autocrine negative regulator of the quiescent resting endothelium (Scharpfenecker 
et al. 2005). In contrast to ANG1, ANG2 triggers an inflammatory response by 
activating the endothelium and inducing vascular permeability (Roviezzo et al.
2005).
4.3 Regulation of TEM biology
Although it has been shown that TIE2 mediates quiescence in HSCs (De Palma et 
al. 2005; Arai et al. 2004), the significance of TIE2 expression by TEMs is currently 
unknown, but it is possible to speculate on the possibility that TEMs are recruited 
to tumors via ANG2/TIE2 interaction. Of note, expression of ANG2 is known to be
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up-regulated in tumors and inflamed tissues as compared to normal, quiescent 
tissues (Nasarre et al. 2009), and activated ECs appear to be a major source of 
ANG2, at least in the mouse (Fiedler et al. 2004). In support of a putative 
chemoattractant role of ANG2, Lewis et al. showed that human peripheral blood- 
derived monocytes respond to ANG2 with both chemotaxis and altered cytokine 
release (Murdoch et al. 2007). Similarly, work from our laboratory suggests that 
human peripheral blood mononuclear cells enriched in TIE2+ monocytes migrate 
towards ANG2 in vitro. Because ANG2-induced chemoattraction of monocytes is 
inhibited by anti-TIE2 neutralizing antibodies (Venneri et al. 2007), it is likely that 
this response is mediated by engagement of the TIE2 receptor. Recently, to 
investigate the effects of ANG2 on the phenotype and function of TEMs in tumors, 
Lewis and co-workers (Coffelt et al. 2010b) used a transgenic mouse model in 
which ANG2 was specifically over-expressed by endothelial cells. Syngeneic 
tumors grown in these ANG2 transgenic mice were more vascularized and 
contained greater numbers of TEMs than those in wild-type mice. However, it is 
currently unknown whether ANG2 directly regulates TEM homing/function in 
tumors, and whether targeting ANG2 or its receptor, TIE2, could represent a 
therapeutic strategy to impair TEM activity in tumors.
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Aim of the work
In this work, I studied monocyte and macrophage heterogeneity in blood and 
tumors, in order to identify molecular pathways regulating the pro-angiogenic 
activity of TEMs and their lineage relationships with distinct monocyte and TAM 
subsets. Furthermore, I investigated the role of TIE2 receptor in TEM biology and 
pro-angiogenic activity.
The first aim of this work was to identify the best-performing TEM purification 
protocol. Flow sort is the gold standard to isolate highly purified cell subsets in 
case multiple markers are required for their isolation (Dirks 2008). I flow sorted 
TEMs, TIE2- TAMs and ECs from tumors grown subcutaneously in Tie2p/e-GFP 
transgenic mice. In this model, GFP expression can be conveniently used to 
discriminate TEMs from other tumor-infiltrating myeloid cells. However, the low 
frequency of TEMs among tumor-infiltrating CD11b+ cells and their weak GFP 
expression level represent technical challenges for the purification of GFP+ TEMs 
from tumors grown in Tie2p/e-GFP transgenic mice. Moreover, in Tie2p/e-GFP 
transgenic mice both TEMs and ECs express GFP. These factors together 
contribute to increase the risk of contamination from other cell types, ECs in 
particular. Consequently, I compared different sorting strategies to test the 
presence of contaminating ECs in TEM preparations and identified the best sorting 
formula to isolate EC-free, tumor-derived macrophage subsets.
The second aim of this work was to determine the gene expression signature of 
tumor-infiltrating TEMs. To gene profile TEMs, TIE2- TAMs and ECs I employed a 
quantitative PCR (qPCR) approach because it allows for identifying low- 
abundance transcripts from small amounts of mRNA. I used low-density qPCR 
arrays with standardized fluidics, which ensure reproducibility, inter-sample
37
comparison and high-throughtput analysis. I analysed ~300 genes previously 
implicated in angiogenesis, tissue remodeling, immune response, cell adhesion, 
chemotaxis, neural guidance and vascular morphogenesis. TEM specific markers 
have been validated by FACS analysis and immunofluorescence staining in two 
different tumor models: N202 tumors grown subcutaneously in Tie2p/e-GFP 
transgenic mice (De Palma et al. 2005) and mammary tumors spontaneously 
arising in MMTV-PyMT transgenic mice previously transplanted with Tie2p/e-GFP 
BM cells (De Palma et al. 2008).
The third aim of this work was to investigate the phenotypic and functional 
relationships between tumor-infiltrating TEMs and circulating monocytes. Blood 
monocytes are considered the precursors of tumor-infiltrating macrophages. I then 
analysed the surface marker and gene expression profiles of blood monocyte 
subsets and compared them with those of tumor-infiltrating TEMs and TIE2- 
TAMs.
Finally, the fourth aim of this work was to study the in vivo role of the TIE2 receptor 
in TEM biology. To investigate this, I implemented a LV platform, recently 
developed in our laboratory (Amendola et al. 2009), that allows for stable and safe 
delivery of siRNA sequences to primary cells. I selected a highly effective siRNA 
sequence, which I employed to knock down TIE2 in vivo. Since hematopoietic 
stem/progenitor cells require TIE2 for their maintenance in the stem cell niche 
(Arai et al. 2004), I implemented advanced features in the LV platform, including 
conditional expression and post-transcriptional regulation of the siRNA expression 
cassette. Such modifications of the LV platform enabled highly efficient Tie2 gene 
knock down in TEMs in vivo and helped to unveil the role of the angiopoietin/TIE2 
pathway in the regulation of tumor angiogenesis by TAMs.
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Results
5 Isolation of highly purified tumor macrophage subsets
To gene profile TEMs and TIE2- TAMs, I chose a quantitative PCR (qPCR) 
approach because it allows for identifying low-abundance transcripts from small 
amounts of mRNA. I used low-density qPCR arrays with standardized fluidics, 
which ensure reproducibility, inter-sample comparison and global analysis. I sorted 
TEMs, TIE2- TAMs and ECs from N202 mammary tumors grown subcutaneously 
in Tie2p/e-GFP transgenic mice (De Palma et al. 2005); in this model, GFP 
expression can be conveniently used to discriminate TEMs from other tumor- 
infiltrating myeloid cells.
5.1 Identification of the best-performing celi sorting formula
Purification of GFP+ TEMs from tumors grown in Tie2p/e-GFP transgenic mice 
presents with several technical challenges, due to the low frequency of TEMs 
among tumor-infiltrating CD11b+ cells and their weak GFP expression level. 
Moreover, in Tie2p/e-GFP transgenic mice both TEMs and ECs express GFP. 
These factors together contribute to increase the risk of contamination from other 
cell types, ECs in particular. To address this issue, I first developed a model to test 
the presence of contaminating ECs in TEM preparations. I sorted TEMs as GFP+ 
CD45+ CD11b+ cells (n=2) and ECs as GFP+ CD45- CD11b- cells (n=2), and 
analyzed a panel of genes by qPCR analysis. To test for ECs contamination, I took 
into account only the genes whose expression was up-regulated more than 4-fold 
in ECs as compared to TEMs {Agtr2, C3, Cell9, Cd34, Csf1, Ece1, Edn1, Fn1, 
1112b, 116, 117, Nos2, Smad7, Angptl, Angpt2, Tie2, VEGFR1, VEGFR2) and found 
a striking correlation in the expression level of such genes in the two cell
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Angpt2
Angpt2
CD11b-CD31+ GFP+ ECsCD11b- CD45- GFP+ ECs
Illustration 11: Identification of the best-performing cell sorting formula for TEM isolation. qPCR  
analyses of a gene panel (see heading 5.1 for details) in TEMs sorted as Tie2p/e-GFP+ CD45+ 
CD11b+ (left) or Tie2p/e-GFP+ CD11b+ CD31-/low (right) cells. Gene expression in TEMs was 
compared with that of tumor-derived ECs sorted as Tie2p/e-GFP+ C D 45- CD11b- (left) or 
Tie2p/e-GFP+ CD31+ CD11b- (right). In the graph on the left, the slope of the regression line 
was approximately equal to one, suggesting that ECs substantially contaminated the TEM  
sample. The graph at right shows that inclusion of CD31 as a negative (TEMs) or positive (ECs) 
gating marker eliminated the source of EC gene contamination in the TEM sample, thus 
providing for accurate isolation of TEMs from tumors.
populations (Illustration 11). The slope of the regression line was approximately 
equal to one, which suggested that either these genes were coordinatedly 
expressed at a constant ratio by the two cell types, which is very unlikely, or that 
ECs substantially contaminated the TEM sample. By assuming that TEMs and 
tumor ECs contain the same amount of mRNA per cell, the extent of contamination 
estimated by the intercept value of the regression line corresponded to 23 32 (about 
10% ECs in the TEM preparation).
I then implemented the sorting strategy by introducing a dump channel to exclude 
PECAM1/CD31+ ECs. After vital staining and exclusion of 7-Amino-Actinomycin 
D+ (7AAD) cells, I sorted TEMs as Tie2p/e-GFP+ CD11b+ CD31-/low cells. The 
improved sorting strategy eliminated the source of EC gene contamination in the 
TEM sample (Illustration 11) and provided for accurate isolation of TEMs from 
tumors. Concerning the potential contamination of the two cell fractions by other
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Illustration 12: A. Flow cytometry analyses of N202 tumors grown subcutaneously in wild-type 
FVB mice (n=4) and made into single cell suspensions shows that the vast majority of tumor- 
infiltrating myeloid cells (gated as CD11b+ cells, dot plot on the left) are highly enriched in 
F4/80+ or CD48+ macrophages (dot plots on the right). One representative experiment is shown. 
To sort TEMs, N202 mammary tumors were grown subcutaneously in Tie2p/e-GFP transgenic 
mice and made into single-cell suspensions. Before cell sorting, CD11b+ myeloid cells were 
magnetically enriched (shown in panels B and C after magnetic enrichment). The sorting 
procedure is shown in the dot plots at left. The GFP+ 7A AD - CD11b+ C D 31- TEMs were then 
sorted (E; panel D shows cells obtained from tumors inoculated in wild-type mice and processed 
as above). Right panels show re-analysis of sorted TEMs (F), that were virtually all 7A AD - (G), 
CD11b+ C D 31 - (H) and GFP+ (open black line in I; open blue line indicates sorted 7A AD - G F P - 
CD11b+ C D 31- cells, i.e. T IE 2 - TAMs).
cell types, the cytospin data confirmed the flow cytometry data (Illustration 16 on 
page 45) that sorted TEMs are >94% pure monocytes/macrophages and TIE2-
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TAMs are >93% monocyte/macrophage cells, with rare neutrophils/eosinophils 
accounting for up to 5-6% of the total cells.
5.2 Validation of sorted tumor macrophage subsets
In N202 tumors, the vast majority of the tumor-infiltrating CD11b+ cells were 
F4/80+ and CD48+ (77±6% and 88±5%, respectively; mean frequency of marker 
positive cells ± SD; n=4), thus representing myeloid cells highly enriched in TIE2- 
TAMs (Illustration 12A). I sorted TEMs as Tie2p/e-GFP+ CD11b+ CD31low/-, 
TIE2- TAMs as Tie2p/e-GFP- CD11b+ CD31low/- and ECs as Tie2p/e-GFP+ 
CD11b-CD31+ cells (Illustration 12B-I). To validate the sorted cell populations, I 
measured the expression of the hematopoietic lineage-specific marker 
Ptprc/Cd45, the macrophage-specific marker F4/80, the EC-specific marker 
Vegfr2 (Flk1), and Tie2, in TEMs, TIE2-TAMs and ECs (n=2-4 biological samples) 
by qPCR (Illustration 13). Both TEMs and TIE2- TAMs expressed high-level Cd45 
and F4/80, which confirmed their hematopoietic origin and monocyte/macrophage 
identity. Of note, Tie2 expression was significantly higher in TEMs than in TIE2- 
TAMs (~20-fold; t-test: p<0.05; n=4).
To analyze the presence of hematopoietic progenitors in sorted cell populations, I
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Illustration 13: Gene expression analysis of FACS-purified TEMs (n=4), T IE 2- TAMs (n=4) and 
ECs (n-2). Results show A C T values (mean ± SEM) over reference gene Gapdh. The lower the 
ACt, the higher the expression level. TEMs and T IE 2 - TAMs express Cd45 (pan- 
hematopoietic-specific marker) and F4/80 (macrophage-specific marker) to similar extent 
Vegfr2 (endothelial-specific marker) is expressed robustly only by ECs. TEMs express Tie2 to a 
significantly higher extent than T IE 2 - TAMs (p<0.05).
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Number of plated cells
5,000 20,000 100,000
TEMs 0 0 0
TIE2-TAMS 0 0 3
Unfractioned BM cells 3 19 112
lineage negative BM cells 36 132 confluent
Table 1: Number of colony forming cells (CFC) arising 
from sorted TEMs and TIE2- TAMs
studied the clonogenic activity of TEMs and TIE2- TAMs in colony-forming cell 
(CFC) assays. Sorted TEMs did not generate hematopoietic colonies (Table 1), 
indicating that they are virtually devoid of hematopoietic progenitors. Exceedingly 
few colonies formed upon seeding of TIE2-TAMs (Table 1).
6 Tumor TEMs are monocytes/macrophages expressing a 
distinguishing gene signature
To investigate the nature of TEMs, I measured the expression of 280 genes 
previously implicated in angiogenesis, tissue remodeling, immune response, cell 
adhesion, chemotaxis, neural guidance, vascular morphogenesis, in TEMs (n=3), 
TIE2- TAMs (n=3) and ECs (n=1). I extended the gene expression analysis to
EC genes Hematopoietic cell genes
f— 15
Q  io-
TIE2-
=  ECs —  TEMs —  TAMs
Illustration 14: qPCR-based, multi-gene array analysis of TEMs (n=3), T IE 2 - TAMs (n=3) and 
ECs (n=1) showing the expression level (ACT vs. (32m) of relevant EC (left panel) and 
hematopoietic/myeloid (right panel) genes. TEMs and T IE 2- TAMs robustly express classic 
hematopoietic/myeloid genes, but not EC genes.
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resting peritoneal macrophages (PMs; sorted as 7AAD- CD11b+ F4/80+ CD31L0W 
cells; n=2) and neutrophils/MDSCs isolated from the spleen of N202 tumor-bearing 
mice (sorted as 7AAD- CD11b+ GR1+ cells; n=2).
6.1 Genes highly expressed in TEMs
The expression profile of TEMs clearly indicated that they belong to the 
monocyte/macrophage lineage and are distinct from ECs. Indeed, TEMs robustly 
express typical myeloid genes, but low to negligible amounts of EC genes 
(Illustration 14). A list of the genes highly expressed in TEMs and grouped by 
function is shown in Illustration 15. Among the highly expressed monocyte- 
macrophage genes, were CSF1 receptor (Csf1r/Cd115), Fc receptors (Fcgrl] 
Fcgr2b; Fcgr3), fractalkine receptor (Cx3cr1), macrosialin (Cd68), F4/80, Cd14, 
scavenger receptors (mannose receptor Mrc1; macrophage scavenger receptors 
Msr1 and Msr2\ hemoglobin-haptoglobin scavenger receptor Cd163; membrane- 
bound scavenger receptor/cytokine Cxcl16), endopeptidases (metalloproteases,
cathepsins) and several integrins. In addition, TEMs express
Myeloid
markers Endopeptidases
Scavenger
receptors Cytokines Chemokines Adhesion
Transcription
factors
Gene ACt Gene ACt Gene ACt Gene ACt Gene ACt Gene ACt Gene ACt
Cd68 2.5 Ctss 0.8 Mrc1 3.0 111b 2.4 Ccl4 1.8 ItgbS 4.7 Statl 3.7
Cd14 2.9 Ctsb 2.0 Msr1 4.1 Tnf 4.0 Ccl2 2.4 Itgbl 5.0 Stat3 5.1
Fcgr3 3.1 Ctsz 2.3 Msr2 4.4 Tgfbl 4.2 Cxcl10 2.9 Itgam 5.2 Nfkb2 5.9
C sflr 3.2 Ctsl 3.8 Cxcl16 4.7 1110 4.4 Cxcl9 4.3 Itga5 7.6 Ski 6.1
Ptprc 3.7 Mmp14 5.7 Cd163 6.3 Vegfa 4.5 Ccl5 4.3 Itgav 7.8 Nfkbl 6.4
Fcgr2b 3.9 Adam17 6.0 II6 5.1 Cxcl16 4.7 Itga6 8.1 Fli1 6.8
Fcgrl 4.2 Adam 15 6.1 I11 a 5.2 Cxcl13 5.1 Itgax 8.1 Ikbkb 7.9
Cd86 4.4 Mmp12 6.5 Sema4d 6.1 Ccl3 5.4 Itga4 8.8 Smad7 8.2
Itgam 5.2 Mmp13 8.4 Pdgfb 7.2 Cxcl11 6.6 Pecaml 9.8 Smad3 9.0
Cx3cr1 5.2 Mmp2 8.5 Ifnbl 7.7 Cxcl14 7.7 Sell 10.3 Stat4 10.7
Emr1 5.3 Mmp9 9.6 Csf1 7.8 Cxcl12 10.6
Cd4 7.9 Mmp3 9.9 1118 8.2
Vegfb 8.2
Mfge8 8.4
1115 8.6
Csf3 9.1
Igf1 9.3
Ecgfl 9.5
Pgf 10.5
Illustration 15: Genes highly expressed in TEMs and grouped by function. A C T was measured vs. 
B2m. The lower the ACr the higher the expression level.
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Tie2- TAMs TEMs
Illustration 16: Morphology (May-Grunwald-Giemsa staining) of TIE2- TAMs (left panel) and 
TEMs (right panel) FACS-sorted from N202 tumors grown in Tie2p/e-GFP transgenic mice (n=2). 
Arrows indicate large macrophages containing conspicuous cytoplasmic phagosomes. Scale 
bar: 30pm. Photos are representative of n -25  photos/sample.
monocyte/macrophage-derived cytokines {111 a] 111 b] 116; Tnf; Tgfbl), chemokines 
(Cc/4; Ccl3/Mip1alb; Cxc/70; Cxc/9; Cxcl11) and classic pro-angiogenic factors 
{Vegfa\ Vegfb; Sema4d\ Pdgfb; lactadherin Mfge8; thymidine phosphorylase 
Ecgf1\ placental growth factor Pgf).
6.2 Morphological analysis of tumor macrophage subsets
Morphological analysis of FACS-sorted cells (n=2; Illustration 16) showed that 
TEMs are a homogeneous cell population with typical monocyte/macrophage 
morphology (>94% of the cells with bean-shaped nucleus and large cytoplasm). 
On the other hand, TIE2- TAMs displayed a greater extent of morphological 
heterogeneity and contained both monocyte-like cells and large macrophages with 
features of activated phagocytes (rounded nucleus; large cytoplasm with 
numerous vacuoles). The cell morphology corroborated the gene expression data 
that both TEMs and TIE2- TAMs belong to the monocyte/macrophage lineage.
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6.3 Genes differentially expressed between TEMs and TIE2- TAMs
A comparison between the gene expression profile of TEMs and TIE2- TAMs 
revealed that the two monocyte/macrophage subsets were highly related 
(Illustration 17). However, TEMs differed significantly from spleen-derived GR1 + 
CD11b+ neutrophils/MDSCs, PMs and tumor-derived ECs.
Statistical analysis of the data (see heading 6.3.a for details) revealed several 
differentially expressed genes between TEMs and TIE2- TAMs (29% at p<0.05; 
Table 2 and Table 3). Among these, Arginasel (Arg1) and several scavenger 
receptors (Cd163; stabilin-1 (Stabl); MrcT, Msr2 (Taylor et al. 2005)) were up- 
regulated, while Nos2, pro-inflammatory and anti-angiogenic molecules (111b;
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Illustration 17: One-dot-one-gene representation of the expression profile (280 genes analyzed) 
of tumor-derived TEMs (n=3), T IE 2 - TAMs (n=3) and ECs (n=1), 
GR1+CD11b+ neutrophils/MDSCs (n=2; isolated from the spleen 
of tumor bearing mice) and peritoneal macrophages (PMs; 
n=2), analyzed by qPCR. Each one-dot-one-gene plot 
compares two cell types, as indicated. The data 
show that TEMs are highly related to T IE 2- 
TAMs (Pearson linear correlation: 
0.926), but sharply differ from
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Ptgs2/Cox2; U12a\ Tnf; Cc/5; Cxc/10; Cxcl11) were down-regulated in TEMs vs. 
TIE2- TAMs. With reference to the M1-M2 polarization paradigm proposed by 
some authors (Mantovani et al. 2002), the enhanced expression of scavenger 
receptors and the down-regulation of inflammatory mediators by TEMs would 
place them at the M2-extreme of the polarization window (i.e. TEMs are 
significantly more M2-skewed that TIE2- TAMs), consistent with their marked pro- 
angiogenic and pro-tumoral activity (De Palma et al. 2005; De Palma et al. 2007). 
Among the most differentially expressed genes were also the hyaluronan receptor- 
1 (Lyvel), neuropilin-1 (Nrp1), stromal cell derived factor-1 (Cxcl12/Sdf-1), insulin 
growth factor-1 (Igf1) and Toll-like receptor-4 (Tlr4), all of which were upregulated 
in TEMs. The finding of several differentially expressed genes strongly suggests 
that TEMs represent a distinct subset or differentiation state of TAMs.
Up-regulated genes
Fold more ACt p value Fold more ACt p value
Cd163 15.8 6.3 *** Timp2 2.8 4.5 **
Lyvel 14.1 6.1 *** Plxndl 2.8 6.2 **
ig fi 8.2 9.3 *** Efnal 2.7 12.6 **
Stabl 6.4 5.5 *** Slamfl 2.6 14.6 *
Mrc1 5.3 3.0 *** Fcgr3 2.6 3.1 *
Sema6d 5.2 15.2 kkk Angptl 2.6 14.2 *
Nrp1 4.6 6.3 *** Sema3c 2.6 12.3 *
Cxcl12 4.4 10.6 •kick Timp3 2.5 12.2 *
Thbs3 4.3 12.1 kkk Kit 2.5 14.9 *
Cxcl13 4.3 5.1 kkk Sdc2 2.5 9.1 *
Efnb2 4.2 12.9 kk Efnbl 2.5 12.0 *
Neo1 4.1 15.1 kk Cdh5 2.4 11.6 *
Plxna3 4.1 12.8 kkk Plxnb2 2.4 6.3 *
Itga2 4.0 16.3 k Il4ra 2.3 5.1 *
Plxnal 3.6 8.1 kkk 111 Ora 2.2 6.5 *
Msr2 3.5 4.4 kkk Arg1 2.2 5.7 *
Tlr4 3.5 7.8 kk Hpse 2.1 5.6 *
Plxna4 3.1 10.9 kk Serpinb2 2.1 9.8 *
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Up-regulated genes
Fold more ACt p value Fold more ACt p value
Edg1 3.0 8.1 
Fcgr2b 2.9 3.9
Itgbl 2.1 5.0
Table 2: Genes up-regulated in tumor-derived TEMs as compared to TIE2- TAMs.
Down-regulated genes
Fold less ACt p value Fold less ACt p value
111 b -6.6 2.4 *** Ptprc -2.7 3.7 **
Ptgs2 -5.0 5.5 •kick Ctss -2.7 0.8 kk
114 -4.0 12.0 kkk Tgfbl -2.6 4.2 k
Nos2 -3.9 8.8 k kk 1118 -2.6 8.2 k
Ccrl -3.8 7.6 k kk Sell -2.5 10.3 k
1112a -3.6 16.2 kk Ccr2 -2.5 5.8 k
Smad7 -3.6 8.2 kkk 1112b -2.5 11.8 k
Bcl2l1 -3.2 6.6 kk Nfkb2 -2.5 5.9 k
Stat4 -3.1 10.7 kk Fas -2.4 9.8 k
Tnf -3.1 4.0 kk Gusb -2.4 4.9 k
1113 -3.1 12.8 kk Smad3 -2.4 9.0 k
Actb -3.0 1.0 kk Socsl -2.4 6.6 k
Edn1 -3.0 11.0 kk Bax -2.4 6.2 k
Ccl5 -3.0 4.3 kk Pgk1 -2.4 4.1 k
H2-Ea -3.0 5.1 kk Ski -2.3 6.1 k
Vegfa -2.9 4.5 kk Csf1 -2.3 7.8 k
111 a -2.9 5.2 kk Ctla4 -2.2 12.9 k
Cxciio -2.8 2.9 kk Statl -2.1 3.7 k
Cd80 -2.8 9.1 kk Tnfrsf18 -2.1 12.0 k
Ece1 -2.7 13.1 k Tbx21 -2.1 12.1 k
Cxcl11 -2.7 6.6 kk
Table 3: Genes down-regulated in tumor-derived TEMs as compared to TIE2- 
TAMs.
6.3.a Statistical model
To rigorously identify differences between TEMs and TIE2-TAMs, in collaboration 
with the institutional center for statistics at the Vita-Salute San Raffaele university,
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I implemented in R (http://www.R-project.org) a multivariate regression model, 
similarly to the model implemented in sas (Yuan et al. 2006), which computes over 
the whole dataset and estimates the fold-change in gene expression for each 
single target gene. This model jointly evaluates the role of different variables of 
interest providing for: (i) statistical significance of the observed differences in 
expression level across the whole set of experimental samples; (ii) identifying the 
experimental variables that significantly contribute to explain the differences in 
expression levels; (iii) subtracting experimentally introduced biases to obtain a 
stringent estimate of the actual biological differences. Detailed statistical methods 
are presented in material and methods section.
6.3.b Validation by FACS and IF staining
I then validated the gene expression results by protein analysis, either by 
immunofluorescence staining (IFS) and confocal microscopy of tumor sections 
(Illustration 18) or by flow cytometry of tumor-derived cell suspensions (Illustration 
19). I employed two different tumor models: N202 tumors grown subcutaneously in 
Tie2p/e-GFP transgenic mice (De Palma et al. 2005) (n=5 for IFS; n=3-7 for flow 
cytometry); and mammary tumors spontaneously arising in MMTV-PyMT 
transgenic mice (Lin et al. 2003) previously transplanted with Tie2p/e-GFP BM 
cells (n=4 tumors from 4 mice for IFS), as described (De Palma et al. 2008). 
Whereas in Tie2p/e-GFP transgenic mice both TEMs and ECs express GFP 
(Illustration 18A), in Tie2p/e-GFP BM-transplanted mice only TEMs are GFP+ 
(Illustration 18B). GFP+ F4/80+ TEMs were frequently located in stromal tumor 
areas, whereas GFP- F4/80+ TAMs were evenly distributed throughout the tumor 
mass (Illustration 18B).
IFS and/or flow analyses showed differential expression of LYVE1, MRC1, TLR4, 
interleukin-4 receptor-alpha (IL4RA), CD163 and STAB1 -  but not of F4/80, TLR2,
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A
Cd68
B
Illustration 18: Confocal immunofluorescence analysis o f mouse tumors. (A) N202 mammary 
tumors (n=5) grown s.c. in Tie2p/e-GFP transgenic mice. The left panels show GFP+ blood 
vessels and abundant CD68+ macrophages (scale bar: 120pm). High-magnification photos (right 
panels) show perivascular Tie2p/e-GFP+ CD68+ TEMs (arrows); scale bar: 60pm. For each 
tumor, at least 3 sections were analyzed. (B) Mammary tumors spontaneously arising in MMTV- 
PyMT transgenic mice (n=4) previously transplanted with Tie2p/e-GFP BM cells. Abundant 
F4/80+ macrophages are evenly distributed within the tumor mass, whereas Tie2p/e-GFP+ 
LYVE1+ or Tie2p/e-GFP+ MRC1+ or Tie2p/e-GFP+ STAB1+ TEMs are mainly found in stromal 
septa surrounding tumor cell nests. Virtually all the Tie2p/e-GFP+ cells express LYVE1, MRC1 
and STAB1. Note that some of the Tie2p/e-GFP- LYVE1+, MRC1+ or STAB1+ cells may 
represent host-derived, non-transgenic TEMs. Scale bar: 60pm. For each tumor, at least 10 
sections were analyzed for each marker.
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Illustration 19: Flow cytometric analysis of N202 mammary tumors identifies a distinguishing 
TEM signature. A) Flow analysis of some of the genes that were either differentially expressed or 
not differentially expressed between TEMs and T IE 2 - TAMs, gated as Tie2p/e-GFP+ CD11b+ 
7AAD- and Tie2p/e-GFP- CD11b+ 7AAD- cells, respectively. In agreement with the mRNA  
data, TEMs but not T IE 2- TAMs robustly and uniformly express TLR4, MRC1, IL4RA and CD 163 
(left panels, n=3). Genes not differentially expressed by qPCR are similarly expressed by TEMs 
and T IE 2 - TAMs (right panels, n=3). B) Further phenotypic characterization of TEMs and T IE 2- 
TAMs. Note that TEMs do not express KIT, granulocyte (LY6G), inflammatory monocyte (LY6C), 
dendritic cell (CD11c), mast cell (FCER1) and megakaryocyte/platelet (CD41) markers (n=3).
ITGA4 (CD49d) and CD86 -  between TEMs and TIE2- TAMs, in agreement with 
the RNA data (Illustration 18B, Illustration 19). Although the Itgax (Cd11c) mRNA 
was expressed similarly in TEMs and TIE2- TAMs (not present in Table 2 and 3), 
TEMs were CD11c- and TIE2- TAMs markedly CD11c+ by flow cytometry and IFS
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(Illustration 19B). TEMs were KIT- and did not express FCER1, LY6G, LY6C and 
CD41, which are mast cell-, neutrophil-, inflammatory monocyte-, and 
megakaryocyte/platelet-specific markers, respectively (Illustration 19B). Together 
with the mRNA data, these results identify a unique TEM surface marker profile, 
which distinguishes them from TIE2-TAMs and related myeloid-lineage cells.
6.4 TEMs are refractory to pro-inflammatory stimuli
The gene expression data indicated that TEMs have a Th2/M2 phenotype. I 
wondered whether Th1 stimulation could modulate this phenotype. To this aim, I 
stimulated (or left unstimulated) tumor-derived TEMs, TIE2- TAMs and PMs with
PMs TIE2- TAMs TEMs
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Illustration 20: TEMs, like T IE 2- TAMs, are refractory to pro-inflammatory stimuli. In vitro 
stimulation of PMs, TEMs and T IE 2- TAMs with Th1 (LPS + IFNg; black bars) and Th2 (IL4; red 
bars) cytokines, or the same cells left unstimulated (Ctrl; grey bars). Upper and lower panels 
show the expression of Th1 (Nos2,1112a) and Th2 (Arg1, Cell 7) responder genes, respectively. 
The expression of each gene is indicated as fold-change (mean ± 2*SD, n=3) over its expression 
in unstimulated PMs (for PMs) or unstimulated T IE2- TAMs (for TEMs and T IE 2- TAMs). Note 
that TEMs and T IE 2- TAMs are much less responsive than PMs to Th1 cytokine treatment. 
Conversely, Th2 cytokine stimulation elicits a greater response in TEMs and T IE 2- TAMs than in 
PMs. Error bars represent a 95% confidence intervals (Cl = 2*SD), thus non-overlapping Cl 
denote a statistically significant difference (p < 0.05).
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either Th1 (LPS + IFNg) or Th2 (IL4) cytokines (n=3 independent experiments) 
and evaluated the expression of established responder genes (Mantovani et al. 
2002) (Nos2 and 1112a for Th1 responses; Arg1 and Ccl17 for Th2 responses). Th1 
stimulation elicited minor responses in TEMs and TIE2- TAMs, as compared to 
PMs (Illustration 20). Conversely, TEMs and TIE2- TAMs were more responsive 
than PMs to Th2 stimulation. These results indicated that both tumour-derived 
TEMs and TIE2- TAMs display defective Th1 responses but can respond to Th2 
stimuli. Of note, both unstimulated and Th2-stimulated TEMs had higher Arg1 and 
lower Nos2 expression than TIE2- TAMs, in agreement with the gene profile data.
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Illustration 21: Flow cytometry analysis of the blood of Tie2p/e-GFP transgenic mice. A) Virtually 
all the Tie2p/e-GFP+ TEMs (green gate in the dot plot on the left; n=16) are CD11b+ CD115+ 
7AAD- monocytes (dot plot on the right). B) Only a fraction (~30%; n=13) of the CD11b+ 
CD115+ 7AAD- monocytes (dot plot on the left) are Tie2p/e-GFP+ (dot plot in the middle). 
Monocytes from wild-type mice (n=5) were used to set the gate for GFP+ events (dot plot on the 
right). C) Dot plots show the expression of surface markers that can distinguish resident from 
inflammatory monocytes (n-7-10). The CD115+ GFP+ 7AAD- cells were gated and the 
expression of CD43, GR1 and L-selectin (CD62L) analyzed. The vast majority of Tie2p/e-GFP+ 
CD 115+ 7AAD- TEMs are CD43+ G R 1- C D 62L- resident monocytes.
53
7 Blood TEMs are a subset of monocytes
Blood monocytes are commonly considered the natural precursors of 
macrophages. To investigate the origin of tumor-infiltrating TEMs, I analysed 
circulating TEMs, which may be the precursors of their tumor-infiltrating 
counterpart (De Palma et al. 2005). We previously speculated that circulating 
TEMs belong to the myeloid lineage based on their expression of CD11b and 
CD14 in mice and humans, respectively (De Palma et al. 2005; Venneri et al.
2007). However, some cell surface-associated markers are co-expressed by 
endothelial- and hematopoietic-lineage cells (De Palma & Naldini 2006).
7.1 TEMs express resident monocyte marker profile
To better characterize the phenotype of circulating TEMs, I extended the 
phenotypic analysis to the most specific monocyte marker (i.e. CSF1R/CD115, 
(Hume et al. 2002)) and to markers able to distinguish between the two monocyte 
subsets (Sunderkotter et al. 2004). The vast majority of circulating GFP+ cells in 
Tie2p/e-GFP mice were positive for CD115 (84±5%, mean ± SD; n=16; Illustration 
21 A). Of note, only 30±6% (n=13) of the total CD115+ monocytes were GFP+, 
indicating that TEMs represent a subset of circulating monocytes (Illustration 21B). 
The GFP+ TEMs were mostly GR1- (84±5%, n=10), CD62L- (74±6%, n=7) and 
CD43+ (80±6%, n=10), thus expressing a resident monocyte marker profile 
(Illustration 21C).
7.2 Common gene signature of circulating resident monocytes and 
tumor-infiltrating TEMs
I then analyzed gene expression (39 genes of interest, selected among those 
analyzed in tumor-derived cells) in CD115+ GR1- resident and CD115+ GR1 + 
inflammatory monocytes obtained from the blood of tumor-free mice (n=4), and
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Up-regulated Down-regulated
Fold more ACt o value Fold less ACt o value
Arg1 58,7 11,5 : A** Chi3l3/Ym1 -18 0 6,4
Cxcl12 20,5 15,1 A # # \Seli -95 8,1 ***
Lyvel 14,7 12,8 \Ccr2 -56 7,6
Stabl 14,1 16,7 ’> - * * * [Ptg§2.___  -4 5 18,1
Igf1 13,6 15,3 ' : AA A
Cd163 5,2 13,3 . Not differentially expressed
Edg1 4,7 9,0 Angptl \Cx3cr1 Itga4 ,Tbx21
1110 4,4 16,0 ■ . A A A |Angpt2 Egf .114 Tgfbl
Mmp9 3,1 12,3 - A V Ccr7 \Fgf2 Vegfr2 " ■ Tir4
Mrci 2,7 9,9 [CsflR  ’ Flt1A/egfr1 M m pl2 J n f
1112a 2,6 14,0 Cd80 j Ifng \Nos2 Tnfrsf18
Mmp2 2,5 17,6 ; *  ■ !Cd86 \tl1b N rp i
L  _ J=  Concordant expression inresident ys: inflamrnatory mbn^ytes arid TEMs vs; TAMs
= Significantly upreg./downreg. either in res. vs. inflam, monocytes or TEMs vs. TAMs 
[ = Discordant expression in resident vs. inflammatory monocytes and TEMs vs. TAMs
Illustration 22: Genes expressed either differentially or not between resident and inflammatory 
monocytes. The concordant (or less) gene expression in blood-derived resident vs. inflammatory 
monocytes and tumor-derived TEMs vs. T IE 2 - TAMs is shown by a colour code, as indicated. 
***: p < 0.001; **; p < 0.01; *: p <  0.05
compared the results with those obtained with tumor-derived TEMs and TIE2- 
TAMs (Illustration 22). Remarkably, 22 out of 39 genes displayed concordant 
expression in resident vs. inflammatory monocytes and TEMs vs. TIE2- TAMs 
(exact binomial test p=0.003). These included Arg1, Igf1, Cxcl12, Lyvel, Stabl, 
Cd163, Edg1, Mrc1 (up-regulated in resident monocytes and TEMs vs. 
inflammatory monocytes and TIE2- TAMs, respectively) and Sell, Ccr2, 
Ptgs2/Cox2 (down-regulated). Only one gene, 1112a, displayed discordant 
expression, whereas the remainder genes were differentially expressed in either 
resident vs. inflammatory monocytes or TEMs vs. TIE2- TAMs. The association of 
the TEM gene expression signature, which enriches for tissue remodeling vs. pro- 
inflammatory genes, with resident monocytes suggests that resident and 
inflammatory blood monocytes represent two functionally distinct subsets that may 
be differentially committed to generate tumor-infiltrating TEMs and TIE2- TAMs, 
respectively.
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8 Tie2 knock down in hematopoietic cells
The function of the TEM distinguishing marker, Tie2, is still unknown. To 
investigate the role of TIE2 receptor in TEMs I employed a lentiviral platform 
recently developed in our laboratory (Amendola et al. 2009). This platform enables 
the expression of one or more artificial micro-RNAs (amiR) together with a reporter 
gene from polymerase-ll promoters. By replacing the stem sequence of a primary 
micro-RNA (pri-miR) with a sequence targeting the gene of interest (i.e. a siRNA 
sequence, in red in Illustration 23), it is possible to obtain robust expression of the 
amiR in several cell types and to reach the concentration and activity typical of 
highly expressed natural miR without perturbing endogenous miR maturation or 
regulation. Moreover, the option to co-express two amiR in a single LV allows the 
targeting of two different sites in the target transcript, which increase the 
repression of the protein at single vector copy number (VCN) (Amendola et al. 
2009).
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Illustration 23: Design of LVs constitutively expressing either a monocistronic (A) or a bicistronic 
(B) artificial micro-RNA cassette and a marker gene (NGFR) from the EF1a promoter. C: 
Detailed structure of the amiR223(Tie2) showing endogenous sequences from pri-miR223 
(dotted lines), siRNA sequence against Tie2 (red line) and the passenger strand (blue line).
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8.1 Identification of the most effective RNAi sequence against Tie2
Selection of an efficient siRNA sequence still requires empirical validation 
(Takasaki 2009). In order to find a siRNA sequence able to consistently knock 
down the murine TIE2 receptor, I tested five candidate sequences targeting Tie2 
suggested by The RNAi Consortium, a public-private consortium based at the 
Broad Institute of MIT and Harvard (http://www.broadinstitute.org/rnai/trc), and five 
candidate sequences designed against Tie2 using the on-line tool from Invitrogen 
Inc. (http://rnaidesigner.invitrogen.com). No overlapping sequences were present 
between the two groups. To improve gene knock down, I also generated bicistronic 
amiR. I then selected two different pri-miR backbones, because recombinations 
within the LV genome are frequent when tandem repeats longer than -200 bases 
(like pri-miR) are present in the same LV genome (Amendola et al. 2009). I chose 
pri-miR-223 (Amendola et al. 2009) and pri-miR-155 (Chung et al. 2006) 
backbones to clone the selected Tie2 siRNA sequences and generated the 
amiR223(Tie2) and amiR155(Tie2) cassettes, respectively. As control, I employed 
siRNA sequences targeting unrelated genes (amiR223(Luc) and amiR155(LacZ), 
targeting luciferase and p-galactosidase, respectively). Finally, these amiR 
constructs were separately cloned into the intron of an expression cassette made 
of the elongation factor 1a (EF1a) promoter and first intron, and a cDNA for the 
truncated form of the low affinity nerve growth factor receptor (NGFR; Illustration 
23).
To select the best performing anti-Tie2 sequence, I transduced brain endothelial 
cells (bEnd), which express the TIE2 receptor endogenously, with amiR223(Tie2) 
and control amiR223(Luc) LVs. The most effective amiR223(Tie2) LV almost 
completely shut off Tie2 expression as shown by FACS, and reduced its mRNA 
level by 7-fold as compared to the amiR223(Luc) LV (Illustration 24A). To quantify
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Illustration 24: Selection of siRNA sequences against TIE2 in vitro. bEnd (A) and U937-TIE2 (B) 
cells expressing the best performing amiR223(Tie2) (or control sequence, Luc). Right plot in A 
shows Tie2 transcript repression, right plot in B shows TIE2 receptor repression. C) Comparison 
at single LV copy of the best performing amiR223(Tie2) (red) with the best performing 
amiR155(Tie2) (blue) and with the bicistronic amiR223(Tie2)_amiR155(Tie2) (pink) in U937-TIE2
the extent of protein suppression of the different siRNA sequences, I performed 
additional experiments using U937 myelomonocytic cells over-expressing the 
murine TIE2 receptor (U937-TIE2) from a LV cassette containing the phospho- 
glycerate kinase 1 (PGK1) promoter and the Tie2 cDNA. In these cells, the high 
expression level of TIE2 ensures a wide dynamic range of gene expression to 
measure gene knock down. The TIE2 receptor was down-regulated by -10 fold 
(vs. amiR223(Luc)) when the best performing amiR223(Tie2) LV was used at 
multiple copies per genome (Illustration 24B). To compare the best performing 
amiR223(Tie2) LV with the best performing amiR155(Tie2) LV, I monitored cells 
transduced at single LV copy over a long period of time. Both amiR223(Tie2) and 
amiR155(Tie2) LVs achieved a 3 to 4 fold repression in U937-TIE2 cells 
(Illustration 24C).
In order to improve gene knock down even at single VCN, I finally generated 
bicistronic LVs encoding for the two most effective amiR(Tie2) cassettes. I
58
compared the performance of this bicistronic amiR223(Tie2)_amiR155(Tie2) LV 
with that of each monocistronic amiR(Tie2) and monocistronic or bicistronic 
amiR(Ctrl) LVs. U937-TIE2 cells were transduced with these vectors at single VCN 
and analysed by FACS. The bicistronic amiR223(Tie2)_amiR155(Tie2) LV 
repressed TIE2 expression about 10 fold, twice as much as the best monocistronic 
amiR(Tie2) LV, at single VCN (Illustration 24C).
In summary, I have identified two highly efficient siRNA sequences against Tie2, 
each allowing 4-fold repression of TIE2 at single VCN, and up to 10-fold 
repression of TIE2 at single VCN when employed in conjunction.
8.2 Constitutive expression of bicistronic amiR impairs cell growth 
in-vivo and in-vitro
To study the effect of down-regulating Tie2 in hematopoietic cells, I performed a 
BM transplantation experiment. To conveniently track TEMs, Tie2p/e-GFP
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Illustration 25: Vector copy number analysis on day 10 after transduction and on blood 
leukocytes at different time points after transplant. Tie2p/e-GFP group of mice (n=5) received 
untransduced Tie2p/e-GFP BM lineage negative cells. amiR(Tie2) group of mice (n=5) received 
Tie2p/e-GFP BM lineage negative cells transduced with bicistronic amiR(Tie2) LVs. amiR(Ctrl) 
group of mice (n=5) received Tie2p/e-GFP BM lineage negative cells transduced with bicistronic 
amiR(Ctrl) LVs. Blue bars: qPCR for H IV  (total VCN); yellow bars: qPCR for GFP (donor Tie2p/e- 
GFP BM); brown bars: qPCR for NGFR (bicistronic amiR LVs). Note that inconsistencies 
between blue and yellow bars in Tie2p/e-GFP group may be due to differences in qPCR assay 
efficiencies.
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transgenic mice were used as BM donors. BM lineage negative cells were 
transduced with the bicistronic amiR223(Tie2)_amiR155(Tie2) or 
amiR223(Luc)_amiR155(LacZ) LVs, and transplanted into lethally irradiated hosts. 
After hematopoietic reconstitution, the progeny of transduced cells can easily be 
identified by the expression of the marker gene NGFR. Although the VCN of 
bicistronic amiR LVs (measured by qPCR for NGFR sequences) was ~1 in liquid 
culture, it dropped to almost undetectable levels in blood leukocytes of both 
groups of mice already at 5 weeks after the transplant (Illustration 25).
This trend was further confirmed by FACS analysis for NGFR expression on blood 
leukocytes at 11 weeks (bicistronic amiR(Tie2): 8.7% SD=1.3% n=5; bicistronic 
amiR(Ctrl): 10.7% SD=4.2% n=5) and 15 weeks (bicistronic amiR(Tie2): 2.7% 
SD=1.5% n=5; bicistronic amiR(Ctrl): 4.7% SD=2.4% n=5) post-transplant. (Table
4). Since the chimerism of donor BM (measured as GFP VCN) remained stable 
throughout the time window of analysis, an engraftment failure can be excluded. 
Rather, these results suggested the presence of a counter-selection process 
against bicistronic amiR-transduced cells in vivo, regardless of the targeted 
sequence.
To investigate the long term effect of amiR expression on cell fitness, I transduced 
U937-TIE2 cells with LVs expressing various combinations of amiR (including 
mono- and bicistronic LVs), targeting either Tie2 or unrelated sequences (Luc and 
LacZ). During a six weeks period, I measured a steady decrease in the percentage
Bicistronic
amiR(Tie2)
% at 11 
weeks
% at 15 
weeks
Bicistronic
amiR(Ctrl)
% at 11 
weeks
% at 15 
weeks
Average 8.7 2.7 Average 10.7 4.7
SD 1.28 1.54 SD 4.18 2.39
U-test 0.0120 U-test 0.03
Table 4: Percentages of NGFR+ blood leukocytes measured by FACS at the 
indicated time points. U-test: Mann-Whitney test
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Illustration 26: In-vitro counter-selection of LVs carrying amiR155 cassette in U937-TIE2 cells. A) 
Time course analysis of cells transduced with the indicated amiR LVs. Percentages of 
transduced cells (left panel) and TIE2 fold repression (right panel) are reported. Note that cells 
expressing amiR155 either against Tie2 sequence or control sequence (LacZ) lose the 
competition with untransduced cells over time (left plot). Fold repression (right plot) is calculated 
dividing the mean fluorescence intensity (MFI) of T IE2+N G FR - (untransduced) cells by the MFI 
of TIE2+NGFR+ cells in the same sample (internal control). B) Average fold change in VCN at 6 
weeks after transduction as compared to VCN at 10 days after transduction (set equal to 1). A 
value smaller than 1 indicates a decrease in VCN with time.
of NGFR+ (i.e. transduced) cells carrying a pri-miR155 backbone inside the 
expression cassette, independently of the target sequence (Illustration 26). 
Interestingly, Tie2 gene knock down (measured as fold repression) was very high 
one week after transduction with the bicistronic amiR155(Tie2)_amiR223(Tie2) LV 
(19.5 fold vs. amiR223(Luc)_amiR155(LacZ) LVs at multiple LV copies), but 
dropped down to the same level obtained with monocistronic amiR223(Tie2) LV at 
3 weeks after transduction (9.2 fold, Illustration 26A). To discriminate between cell
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counter-selection and LV silencing, I compared the VCN at 10 days after 
transduction with that at 6 weeks after transduction, and found that the VCN 
decreased, on average, by 3-fold in cells carrying bicistronic amiR cassettes, 
whereas it remained stable in monocistronic, amiR223 containing cells (Illustration 
26B). Overall, these results indicate that amiR155 is detrimental to cell 
fitness/viability, and the cells which express it are rapidly counter-selected both in- 
vitro and in-vivo.
9 Conditional Tie2 knock down in mature hematopoietic cells
Although it is reported that the amiR design neither saturates miR pathway 
(Castanotto et al. 2007; Boudreau et al. 2009) nor triggers type I IFN responses 
(Ely et al. 2009), some authors suggest that when very high concentrations of 
RNA duplexes are present inside the cell (whatever method is used to 
introduce/generate it), nonspecific off-target effects, including activation of the 
interferon response, become likely (Cullen 2006; Fish & Kruithof 2004). Moreover, 
hematopoietic stem cells chronically stimulated with type I interferon are 
functionally compromised (Essers et al. 2009). To overcome toxicity and in vivo 
counter selection of amiR-expressing cells (see paragraph 8.2), I implemented two 
features in our LV platform:
1. Conditional expression;
2. Post-transcriptional regulation;
in order to finely tune amiR expression level and de-target its expression from 
HSCs, respectively.
To achieve conditional expression (feature 1) we employed a Tetracycline based 
genetic switch (Vigna et al. 2005). This switch is composed of a proteinaceous 
transactivator (reverse Tetracycline transactivator, rtTA) and a synthetic promoter
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Illustration 27: Conditional LV platform for amiR expression. Prom: promoter of choice; rtTA: 
reverse Tetracycline transactivator; Wpre: Woodchuck hepatitis virus post-transcriptional 
regulatory element; miR126T: micro-RNA-126 target sequence; TRE: Tetracycline regulated 
element; SD/SA: splice donor/acceptor. Red stems inside the primary micro-RNA (pri-miRNA) 
represents artificially inserted sequences against Tie2 or Luc.
(Tetracycline responsive element, TRE) (Urlinger et al. 2000; Gossen & Bujard 
1992). Upon Doxycycline treatment, rtTA binds to TRE and switches on the 
transcription of the downstream gene silencing cassette (Illustration 27).
In order to suppress rtTA expression (feature 2) and, consequently, 77e2 gene 
knock down in HSCs, which require TIE2 for their maintenance in the stem cell 
niche (Arai et al. 2004), I modified the rtTA expression cassette by incorporating 
target sequences for miRNA-126 (miR-126T) in the UTR (Illustration 27). By this 
strategy (Brown & Naldini 2009), rtTA expression is suppressed specifically in 
HSCs via miRNA-mediated mRNA degradation, as only HSCs express high-level 
miR-126 among hematopoietic-lineage cells (Gentner and Naldini, unpublished 
data).
9.1 T\e2 knock down in primary celis
To obtain inducible gene silencing, I placed the rtTA-m2 under the control of the 
ubiquitously active PGK promoter and generated FVB/PGK-rtTA-miR-126T (LV2; 
Illustration 27) transgenic mice by LV-mediated transgenesis, as previously 
described (De Palma et al. 2005). LV2-transgenic mice carrying more than 3
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vector copies per genome were then used as donors of BM cells in all subsequent 
experiments. We transduced LV2-transgenic, BM-derived lineage-negative cells 
(BM-Lin- cells, which comprise cKIT+ SCA1+ long-term repopulating HSCs; 
Illustration 28A) with LV1 (Illustration 27) either expressing amiR(Tie2J or 
amiR(Lucj, together with a marker gene (orange fluorescent protein, OFP), 
enabling the identification of the induced cells. I cultured a small aliquot of the 
transduced cells in vitro for 2 weeks, or transplanted them into irradiated FVB 
mice, to obtain amiR(Tie2) and amiR(Luc) mice (n = 3/group), respectively.
Both amiR(Tie2)- and amiR(Luc)-transduced BM-Lin- cells efficiently upregulated 
OFP expression (> 80% OFP+ cells) as early as 2 days after doxycycline 
treatment in vitro (Illustration 28B). To detect if the primary amiR(Tie2) is not only 
expressed, but also correctly processed inside the cells, I employed a custom 
qPCR-based assay, which detects the 21 nucleotide long ncRNA corresponding to 
the mature form of amiR(Tie2). Two days after doxycycline treatment, amiR(Tie2)- 
transduced cells up-regulated the mature amiR(Tie2) sequence by > 30-fold by 
qPCR (vs. untreated, amiR(Tie2)-transduced cells; Illustration 28C) and 
concomitantly down-regulated the endogenous Tie2 mRNA by > 4-fold 
(corresponding to a 75% reduction) as compared to untranduced or amiR(Luc)- 
transduced cells (Illustration 28D). These results indicate efficient and inducible 
expression, as well as correct maturation, of the primary amiR(Tie2) that 
generates siRNA sequences against Tie2 inside the cells.
9.2 The conditional gene silencing platform is safe in vivo
I then tested if cell counter-selection occurs upon induction of amiR expression. 
Three weeks after BM-Lin- cell transplant, I treated amiR(Tie2) and amiR(Luc) 
mice with doxycycline every third day in order to activate LV1 in BM-derived cells. 
One week and 4 weeks after the first doxycycline administration, I collected the
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blood of the mice from the tail vein and analyzed their blood to score for OFP 
expression and potential hematopoietic counter-selection of OFP+ cells 
(Illustration 29A). At both time points, I measured very similar percentages of 
OFP+ monocytes and granulocytes of both amiR(Tie2) and amiR(Luc) mice 
(indicated by a time ratio equal to 1; Illustration 29B). As expected, at 4 weeks 
after BM-Lin- cell transplant, the chimerism of lymphocytes is not yet complete,
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Illustration 28: Ex vivo validation of conditional Tie2 gene knock down. A: Flow cytometry of LV1- 
transduced BM-Lin~ HSPCs. Panels show freshly isolated, LV2-transgenic, BM-Lin~ HSPCs 
stained with 7AAD, lineage markers (B220; Gr1; Ter119; CD11b), c-KIT, and SCA1. Note that 
viable (7AAD-) BM-Lin~ cells contain bona fide HSCs (Lin~ C-KIT+ SCA1+) at the expected 
frequency (ca. 2-4%). B: Panels show LV2-transgenic, BM-Lin~ HSPCs analyzed 5 days after 
transduction with LV1 (carrying the amiR(Tie2)/OFP expression cassette). Cells were treated 
with doxycycline (or left untreated) starting at day 1 post-transduction. Note that OFP is robustly 
induced in doxycycline-treated cells. C: Doxycycline-mediated induction of the amiR(Tie2) 
sequence in LV2-transgenic, BM-Lin~ cells at day 2 post-transduction with LV1, measured by 
qPCR (fold-change vs. untreated cells). Let7a (a ubiquitously expressed miRNA) was used to 
normalize gene expression. Note that the amiR(Tie2) sequence is not detected in untransduced 
cells (UT) and amiR(Luc)-transduced cells either treated with doxycycline or left untreated. D: 
Tie2 gene knock down in LV2-transgenic, BM-Lin~ cells at day 2 post-transduction with LV1, 
measured by qPCR (fold-change vs. amiR(Luc)-transduced cells treated with doxycycline (*)). 
Error bars represent 95% confidence interval (1.96*SEM).
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Illustration 29: The conditional gene silencing platform is safe in vivo. A: Representative flow 
cytometry analysis of OFP in blood monocytes from mice transplanted with LV2-transgenic, BM- 
Lin- HSPCs transduced with LV1. From left to right: CD115+ monocytes are gated from total 
viable leukocytes and are further analyzed for GR1 and OFP expression; monocytes from a 
mouse transplanted with LV2-transgenic, untransduced BM-Lin~ HSPCs; mouse transplanted 
with LV2-transgenic, BM-Lin~ HSPCs transduced with LV1 and left untreated ( -  doxy); mouse 
transplanted with LV2-transgenic, BM-Lin~ HSPCs transduced with LV1 and treated with 
doxycycline for one week in vivo before analysis (+ doxy; right). B: Flow cytometry analysis of 
blood leukocyte subsets (monocytes: 7AAD- CD115+; granulocytes: 7AAD- C D 115- GR1+; 
lymphocytes: 7AAD- C D115- G R 1-) from amiR(Tie2) and amiR(Luc) mice. The ratio between 
the percentages of OFP+ cells in the indicated leukocyte subset at T2 (7 weeks after transplant; 
3 weeks after doxycycline administration) and T1 (4 weeks after transplant; 1 week after 
doxycycline administration) is shown. Note that lymphocyte chimerism is not yet complete at 4 
weeks after transplant. C: Blood monocyte subsets (inflammatory monocytes: 7AAD- CD11b+ 
GR1+ CD115+; resident monocytes: 7AAD- CD11b+ G R 1- CD115+) in MMTV-
PyMT/amiR(Tie2) and MMTV-PyMT/amiR(Luc) mice 3 weeks after doxycycline treatment (7 
weeks of age).
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since they require at least 6 weeks to develop from donor HSCs. Thus, amiR 
expression is safe for hematopoietic cells in vivo.
As shown in paragraph 7.1, circulating TEMs are bona fide resident monocytes. To 
test if Tie2 knock down affects monocyte subset ratios, I measured blood 
monocyte subsets by flow cytometry in amiR(Tie2) and amiR(Luc) mice, 3 weeks 
after doxycycline treatment (7 weeks of age). I found that Tie2 knock down did not 
change the percentages of monocyte subsets (Illustration 29C). Moreover, 
expression of the amiR(Tie2) did not perturb cell counts and leukocyte composition
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I/lustration 30: Efficient de-targeting o f amiR expression from BM-Lin~ cKIT+ SCA1+ HSCs in 
vivo. Flow cytometric analyses of cKIT and SCA1 expression in either OFP+ or OFP- BM-Lin~ 
cells obtained from amiR(Tie2) and amiR(Luc) mice 7 weeks after BM -Lirr transplantation and 1 
week after the first doxycycline administration. Note that OFP- but not OFP+ BM-Lin~ cells 
contained cKIT+ SCA1+ HSCs at the expected frequency (2-4%), whereas both OFP- and 
OFP+ BM-Lin~ cells contained cKIT+ SCA1- HPCs at the expected frequency (ca. 50%). Error 
bars in the scatter plots represent SEM (n = 6).
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in the blood of transplanted mice (vs. amiR(Luc) mice; data not shown).
To assess if the miR126T-mediated post-transcriptional regulation was effective in 
vivo, I measured OFP expression in BM-Lin- HSPCs from amiR mice. I found that 
OFP expression was virtually absent in primitive HSCs, identified as cKIT+ SCA1 + 
BM-Lin~ cells, but not in cKIT+ HPCs and their prospective progeny (Illustration 
30). These data suggest that rtTA is efficiently suppressed in HSCs but not in 
HPCs, closely recapitulating the expression pattern of miR126.
Overall, these findings indicate robust, safe doxycycline-mediated expression of 
the amiR/OFP expression cassette in the mature progeny of BM-Lin~ cells, but not 
bona fide HSCs, in the transplanted mice.
9.3 Tie2 knock down in tumor TEMs impairs angiogenesis
In order to assess doxycycline-mediated OFP expression and Tie2 knock down in 
TAMs, we challenged both amiR(Tie2) and amiR(Luc) mice with N202 tumor cells 
subcutaneously. Three weeks post-tumor injection, we harvested the tumors and
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Illustration 31: Efficient conditional Tie2 gene knock down in tumor-infiltrating myeloid cells. 
Percentages of A: TAM subsets (TEMs: 7AAD- CD11b+ G R 1- M RCIhigh CD11c~; T IE 2- TAMs: 
7AAD- CD11b+ G R 1- M R C Ilow  CD11c+); B: OFP+ cells within TEMs in MMTV- 
PyMT/amiR(Tie2) and MMTV-PyMT/amiR(Luc) mice at 15.5 weeks of age. C: Conditional Tie2 
gene knock down in MRC1high/CD11c- TEMs infiltrating N202 tumors. TEMs from doxycycline- 
treated amiR(Tie2) mice (fold-change vs. doxycycline-treated amiR(Luc) mice) were fractionated 
into O F P - (left panel) and OFP+ (right panel) cells. Note that Tie2 is silenced only in OFP+ but 
not in O F P - TEMs.
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measured by flow cytometry the percentages of TAM subsets. As shown in 
Illustration 31 A, the relative amounts of TEMs (MRC1HIGH CD11c-) and TIE2- 
TAMs (MRC1L0W CD11c+) were unaffected by Tie2 knock down. Importantly, TEMs 
from both amiR(Tie2) and amiR(Luc) mice expressed similarly high levels of OFP 
(Illustration 31B), indicating comparable expression of the amiR in either groups of 
mice. To quantify the level of Tie2 gene knock down in TEMs, I isolated the OFP+ 
and OFP- fractions of TEMs (CD31L0W MRC1HIGH CD11c-) by cell sorting. 
Statistical modeling of qPCR data (Pucci et al. 2009) showed that the Tie2 mRNA 
was specifically knocked-down in the OFP+ TEMs of amiR(Tie2) mice (Illustration 
31C; 4-fold vs. OFP+ TEMs of amiR(Luc) mice; p < 0.01). These results represent 
molecular evidence for efficient in vivo Tie2 gene silencing in tumor-infiltrating 
TEMs and suggest that Tie2 gene knock down do not detectably alter TEM 
recruitment to the tumors.
To study the effects of Tie2 gene knock down in a model of spontaneous 
tumorigenesis, I generated MMTV-PyMT/amiR(Tie2) and MMTV-PyMT/amiR(Luc) 
mice by BM transplantation (2 independent experiments; n = 12-14 mice/group). 
We treated the mice with doxycycline starting at 4 weeks post-transplant (9.5 
weeks of age), when the angiogenic switch and malignant conversion occur in this 
tumor model (Lin et al. 2006). At 15 weeks of age we euthanized the mice and 
analyzed tumor angiogenesis by flow cytometry and IFS of frozen sections. I 
observed significant differences between MMTV-PyMT/amiR(Tie2) and MMTV- 
PyMT/amiR(Luc) mice. The CD31+ blood vessels of amiR(Tie2) tumors appeared 
smaller, fewer and less perfused (lectin+) than in the controls (Illustration 32A). To 
quantify these observations, we measured the CD31+ or lectin+ area in the 
tumors. Both the relative CD31+ vascular area and the relative lectin+ (perfused) 
vascular area, measured by IFS of tumor sections, were significantly lower in 
amiR(Tie2) than amiR(Luc) mice (Illustration 32B). Flow cytometric analyses
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Illustration 32: Conditional Tie2 gene knock down in TEMs inhibits angiogenesis and impairs 
blood vessel functionality in spontaneous breast tumors. A: Lectin (green), OFP (red) and CD31 
(blue) immunostaining of representative tumor sections of MMTV-PyMT mice transplanted with 
BM-Lin~ cells either transduced with amiR(Tie2) or amiR(Luc) LV1 and analyzed at 15 weeks of 
age. Note the presence of several perfused (lectin+) CD31+ blood vessels in the control, 
amiR(Luc) tumor; the lectin+ CD31+ blood vessels are fewer in the amiR(Tie2) tumor. Note that 
abundant OFP+ cells are present in both amiR(Luc) and amiR(Tie2) tumors; Scale bar: 150 pm. 
Results are representative of 2 independent experiments and 10 tumors/group analyzed. For 
each tumor, multiple sections (3-5) were analyzed. B: Morphometric analyses of the vascular and 
perfused tumor area in sections obtained from same tumors as in A. C: Flow cytometry analysis 
of lectin+ CD31+ C D 45- ECs in same tumors as in A. Each dot in B and C indicates one 
individual tumor analyzed; for each tumor, multiple sections (3-5) were analyzed. Scatter plots 
show mean values ± SEM. Statistical analyses by Mann-Whitney U test. Results combine 2 
independent experiments.
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confirmed the lower frequency of lectin+ CD31+ CD45- ECs in the tumors of 
amiR(Tie2) mice (Illustration 32C). I observed decreased angiogenesis also in 
FVB/amiR(Tie2) mice challenged with subcutaneous N202 mammary tumors (data 
not shown).
I noted that the distribution of OFP+ and OFP- tumor-infiltrating cells differed in 
MMTV-PyMT/amiR(Tie2) and MMTV-PyMT/amiR(Luc) mice. Indeed, there were 
fewer OFP+ (i.e., Tie2 knocked-down) cells associated with perfused (lectin+ 
CD31+) tumor blood vessels in amiR(Tie2) than amiR(Luc) mice (Illustration 33A), 
whereas similar amounts of OFP+ cells surrounded the non-perfused (lectin- 
CD31+) immature vessels in either group of mice. These findings suggest that the 
association of OFP+ myeloid cells (i.e. Tie2 knocked-down TEMs) with newly
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Illustration 33: A: Morphometric analysis of OFP+ cells and their association with CD31+ or 
lectin+ CD31+ blood vessels in tumors of MM TV-PyMT mice transplanted with BM-Lin~ cells 
either transduced with amiR(Tie2) or amiR(Luc) LV1 and analyzed at 15 weeks of age. Results 
combine 2 independent experiments. 611 individual OFP+ cells from 10-11 digital images/group 
acquired at x200 magnification were scored, and their association with blood vessels analyzed. 
Bars show mean value ± SEM. Digital images were obtained from 5-6 tumors from 2 
independent experiments. B: Mammary tumor growth (mean volume ± SEM  at 14.5 weeks of 
age, shown as fold-change vs. tumor volume at 11.5 weeks of age in each individual mouse) by 
MRI-based volumetry of the 10 mammary glands. One experiment is shown. Statistical analyses 
in A and B by Mann-Whitney U test.
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forming blood vessels impeded their maturation to functional (i.e., perfused) tumor 
blood vessels. It should be noted that the frequency of OFP+ TEMs ranged from 
50% to 90% in the tumors of both amiR(Tie2) and amiR(Luc) mice (Illustration 31B 
on page 68), indicating that Tie2 gene knock down occurred in the majority but not 
all tumor-infiltrating hematopoietic cells. Nevertheless, Tie2 gene silencing in 
TEMs produced statistically significant tumor growth inhibition in 1 of the 2 
independent experiments performed (26% inhibition measured by MRI-based 
volumetry at 11.5 and 14.5 weeks of age; p < 0.05; Illustration 33B), supporting the 
relevance of the observed vascular changes. In summary, Tie2 knock down by 
RNAi reduced tumor angiogenesis and blood vessel functionality in MMTV-PyMT 
spontaneous breast tumors. Thus, TIE2 represents a crucial effector of the pro- 
angiogenic activity of TEMs.
72
Discussion
10 TEMs are distinct from ECs
Our gene expression data demonstrate that TEMs are distinct from endothelial- 
lineage cells and represent a subset of tumor infiltrating macrophages expressing 
a distinguishing gene signature, which is consistent with enhanced pro-angiogenic 
and tissue-remodeling activity and lower pro-inflammatory activity. The carefull 
choice of surface markers which made it possible to highly purify TEMs was 
instrumental in the identification of their gene expression signature. In particular, a 
negative selection marker for ECs was crucial to avoid EC contamination in the 
TEM preparation. This apparent link between TEMs and ECs can be explained by 
the reported close association of TEMs with blood vessels (De Palma et al. 2003).
Several studies have reported that mononuclear cells expressing a reporter gene 
from Tie2 transcription regulatory elements are recruited to tumors and ischemic 
tissues (De Palma et al. 2003; Asahara et al. 1997; Ahn & Brown 2008). Based on 
the assumption that Tie2 expression is specific for ECs, these TIE2+ cells were 
often interpreted as EPCs, even if they expressed hematopoietic or myeloid 
markers (Modarai et al. 2005) and were often found outside of the vessel wall 
(Asahara et al. 1999). By implementing stringent combinations of gene marking 
and imaging approaches, previous work from our lab showed that these TIE2+ 
mononuclear cells indeed represent myeloid cells (De Palma et al. 2005). Here, I 
conclusively demonstrate that Tie2 expressing cells recruited to tumors do not 
belong to the EC lineage and are bona fide monocytes/macrophages. By 
comparing tumor-derived TEMs, TAMs and ECs, I show that the gene expression 
profile of TEMs is similar to that of TAMs but clearly distinct from that of ECs. 
Further data support the non-EC nature of TEMs. Indeed, TEMs (i) robustly
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express hematopoietic-specific markers (e.g. CD45, F4/80 and miR-142, the latter 
shown by using a microRNA-regulated reporter transgenic mouse line); (ii) 
express low-to-negligible levels of EC-specific genes (e.g. Vegfr2 and VE- 
Cadherin/Cc//75); (iii) do not incorporate in the tumor endothelium and often reside 
in perivascular spaces. These findings strongly support the notion that BM-derived 
Tie2 expressing cells repeatedly observed in tumors are not EPCs. Whether true 
EPCs contribute to tumor angiogenesis is still a matter of debate, with recent 
reports showing a contribution limited to selected experimental conditions, such as 
tumors treated by vascular-disrupting agents or chemotherapy (Shaked et al.
2008).
11 Overlapping function and phenotype between TEMs and 
other mononuclear subsets
Although TEMs do not physically incorporate in the tumor endothelium, they seem 
required for tumor angiogenesis (De Palma et al. 2007). Within the panel of 
interrogated genes, many genes previously implicated in tumor angiogenesis were 
among the most differentially expressed between TEMs and TAMs. One such 
gene is Lyvel (14-fold up), which encodes for the hyaluronan receptor-1 
expressed on lymphatic ECs and subsets of macrophages. Because TEMs also 
express Stabl (stabilin-1, a hyaluronan receptor (Politz et al. 2002); 6.4-fold up) 
and Cd163 (hemoglobin/haptoglobin scavenger receptor; 15.8-fold up), it is likely 
that the previously described LYVE1+ STAB1+ CD163+ macrophages observed in 
tumors, wounds, placenta and remodeling adipose tissue (Schledzewski et al. 
2006; Cho et al. 2007; Bockle et al. 2008), indeed represent TEMs. In these 
reports, a common feature of the described LYVE1+ STAB1+ CD163+ 
macrophages is the juxtaposition with sprouting ECs, which suggests a functional 
role as cellular chaperones for endothelial tip cells (Fantin et al. 2010).
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In the last months, a very interesting paper reported that the tumor 
microenvironment hosts functionally distinct TAM subsets (Movahedi et al. 2010). 
The Authors identified 2 subsets among CD11b+ F4/80+ TAMs based on MHC-II 
expression. MHC-IIL0W TAMs have striking similarities with TEMs when compared 
with the other TAM subset (MHC-IIHIGH TAM and TIE2- TAMs respectively); indeed 
both 1) show a superior pro-angiogenic activity; 2) share the same gene 
expression signature (high levels of Lyvel, Cd163, Stabl, Mrc1, Arg1, Il4ra, and 
low levels of Mhc-ll (alias H2-Ea), 111b, Nos2, Ptgs2, Ccl5, CxcHO, Cxcl11)’, 3) can 
be distinguished from the other respective subset by the same surface marker 
profile (MRC1+ CD11c- MHC-IIL0W); 4) are bigger (as measured by light scatter);
5) accumulate during progression of several cancer. Unfortunately, the Authors did 
not find differences in Tie2 expression levels between MHC-IIL0W and MHC-IIhigh 
TAMs. It is very likely that, since the FACS panel employed by the Authors to 
isolate the TAM subsets did not include a negative selection marker for ECs (which 
express high levels of Tie2), a small contamination of ECs in both MHC-IIL0W and 
MHC-IIHIGH TAMs may have masked the difference in expression of Tie2. Still, an 
independent lab fully reproduced and expanded my work on TAM subsets.
12 Functional considerations
The identification of a TEM gene signature allows us to formulate some 
hypotheses on the molecular mechanisms of TEM pro-angiogenic activity.
12.1 Extra-cellular matrix and TEMs
As stated before, Lyve-1 and Stabl are up-regulated in TEMs. Tlr4, a toll-like 
receptor implicated in tumorigenesis (Chen et al. 2008), is also preferentially 
expressed by TEMs (3.5-fold up). Whereas LYVE1 and STAB1 binds hyaluronic 
acid (HA), TLR4 binds to its low-molecular weight fragmentation products (Termeer
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et al. 2002; Politz et al. 2002). Interestingly, Tlr4 expression by macrophages has 
been found to mediate remodeling of the lung microenvironment and favor 
subsequent colonization by tumor cells (Hiratsuka et al. 2008). Moreover, HA 
fragments stimulate MMP production, cell migration and angiogenesis in tumors 
(Toole 2004), and up-regulate Irak-M expression by monocytes, deactivating them 
and down-regulating their expression of the anti-angiogenic molecules Tnfa and 
1112a (del Fresno et al. 2005). The preferential expression of Lyvel, Stabl and 
Tlr4 by TEMs among tumor macrophages suggests a role of TEM-HA interactions 
in tumor angiogenesis (Genasetti et al. 2008).
12.2 Soluble mediators
Another gene upregulated in TEMs is Cxcl12 (4.4-fold up), encoding for the 
stromal cell derived factor-1 (SDF1). SDF1 released by TEMs may promote 
angiogenesis by attracting CXCR4+ ECs and other pro-angiogenic cells in the 
tumor microenvironment (Petit et al. 2007). Interestingly, unpublished work from 
our lab indicates that ANG2 neutralization by a novel ANG2-specific monoclonal 
antibody (Brown et al. 2010) impedes the transcriptional up-regulation of Cxcl12 in 
tumor-infiltrating TEMs (Pucci, Mazzieri). Thus, it is possible that the TEM specific 
expression of Cxcl12 may increase their ability to support tumor blood vessel 
morphogenesis in an ANG2-dependent manner.
Angptl (angiopoietin-1, a Tie2 ligand; 2.6-fold up) expressed by TEMs may also 
promote tumor angiogenesis, as Angptl-expressing hematopoietic cells stimulate 
EC sprouting in embryonic tissues (Takakura 2006).
Interestingly, the CXC chemokines Cxcl10 and Cxcl11 were down-regulated in 
TEMs (2.8- and 2.7-fold down, respectively). These chemokines are transcribed 
upon Irf3/Stat1 activation and are potent inhibitors of angiogenesis (Strieter et al. 
2005). Overall, the enhanced expression of several pro-angiogenic molecules by
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TEMs, together with the down-regulation of potent anti-angiogenic mediators (also 
including 1112a, 3.6-foid down; 1112b, 2.5-fold down; Tnfa, 3.1-fold down), may 
account for their non-redundant pro-angiogenic activity in tumors (De Palma et al. 
2007).
12.3 TEMs as cellular chaperones
Vegfa, which is among the most expressed genes in TEMs, was however down- 
regulated in TEMs vs. TAMs (2.9-fold down). This apparent paradox can be 
explained by taking into consideration the preferential localization of TEMs in 
peritumoral areas and their exclusion from necrotic, avascular regions (De Palma 
et al. 2005), suggesting that TEMs are exposed to a less hypoxic 
microenvironment in tumors. Of note, the targeted deletion of Vegfa alleles in all 
myeloid cells (including TAMs) did not decrease the overall amounts of VEGFA 
expressed in the tumors and failed to inhibit tumor angiogenesis and growth 
(Stockmann et al. 2008). These results may thus challenge the notion that TAMs 
represent a non-redundant source of VEGFA in experimental tumors and that the 
cellular localization may be more crucial then the total amount of VEGFA. Indeed, 
it is likely that TEMs exert a requisite pro-angiogenic function by supporting tumor 
blood vessel morphogenesis downstream to VEGF-induced vascular activation 
and EC tip formation. One can envision that TIE2 expression by TEMs regulates 
blood vessel formation in tumors by non-canonical angiogenic mechanisms, such 
as cell-to-cell adhesive interactions (Illustration 34 on page 83). Indeed, the finding 
of a poor association between Tie2 knocked down (i.e., OFP+) TAMs and 
functional (i.e., Iectin+) tumor vessels in MMTV-PyMT tumors supports this view. 
Such scenario is in agreement with a recent study that shows that perivascular, 
TIE2+ macrophages physically interact with the tip cells of nascent blood vessels, 
which also express TIE2, and are essential to promote vascular anastomosis
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during embryonic development (Fantin et al. 2010). Furthermore, it was previously 
shown that, during embryonic development, TIE2 expression by hematopoietic 
cells promotes their adhesion to TIE2+ ECs, and that such interaction stimulates 
angiogenesis in para-aortic splanchnopleural mesoderm explant cultures 
(Takakura et al. 1998).
12.4 Miscellanea
The expression of Nrp1 (Neuropilin-1, a VEGF co-receptor; 4.6-fold up) by TEMs 
might enhance angiogenesis by clustering VEGF in contact with VEGFR2+ ECs, 
as previously described (Takakura 2006). Efnb2 (Ephrin-B2; 4.2-fold up) encodes a 
transmembrane ligand of Ephrin receptors expressed on ECs; the bidirectional 
signaling between ephrin-B2 and Ephrin receptors modulates angiogenesis and 
the development of arteries and veins (Carmeliet & Tessier-Lavigne 2005). 
Semaphorin 6D (Sema6d; 5.2-fold up), a transmembrane protein that binds to 
membrane-bound PlexinBI, may also have pro-angiogenic activity in tumors, as it 
activates VEGFR2-mediated signal transduction (Neufeld & Kessler 2008). The 
enhanced expression of Nrp1, Efnb2 and Sema6d by TEMs may suggest 
activation of ECs by cell-to-cell contacts.
TEMs display up-regulated expression of Edg1 (sphingosine-1-phosphate 
receptor; 3.0-fold up). Edg1 null embryos are hemorrhagic and die in utero, a 
phenotype associated with impaired vascular maturation and defective recruitment 
of perivascular cells to angiogenic blood vessels (Liu et al. 2000). Moreover, 
sphingosine-1-phosphate induces macrophages to acquire an anti-inflammatory 
phenotype (high Arg1, low Nos2 activity (Hughes et al. 2008)), which is consistent 
with TEM phenotype.
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13 TEM precursors
Both mouse and human monocytes can be grouped into functional subsets 
(Geissmann et al. 2010). I found that circulating TEMs belong to the GR1- 
CD62L- CD43+ resident monocyte subset. In addition to previous data from our 
lab showing that TEMs are pro-angiogenic (De Palma et al. 2005; De Palma et al.
2007), a recent report indicated that resident monocytes promote tissue 
angiogenesis in the post-ischemic myocardium (Nahrendorf et al. 2007). Together, 
these data may suggest a developmental and functional relationship between 
circulating resident monocytes and tumor-infiltrating TEMs. New findings described 
here further show that resident monocytes isolated from the blood of tumor-free 
mice and tumor-derived TEMs display a coordinated expression profile, which 
points to a commitment of TEM phenotype/function in the peripheral blood. Arg1, 
Cxcl12, Lyvel, Igf1, Stabl, Cd163, Mrc1 and Edg1, all significantly up-regulated in 
tumor-derived TEMs vs. TIE2- TAMs, were markedly up-regulated in resident vs. 
inflammatory monocytes. Expression of 1112a (an anti-angiogenic molecule) was 
down-regulated in TEMs vs. TIE2- TAMs but unexpectedly up-regulated in 
resident vs. inflammatory monocytes. However, two recent reports have shown 
that both mouse and human resident monocytes rapidly down-regulate 1112 
expression upon their extravasation in vivo (Auffray et al. 2007) or when exposed 
in vitro to experimental conditions mimicking the hypoxic tumor microenvironment 
(Murdoch et al. 2007). The coordinated expression profiles of resident 
monocytes/TEMs and inflammatory monocytes/TIE2- TAMs suggest that 
monocyte heterogeneity in the peripheral blood may reflect the existence of 
precursor populations that are committed to distinct, non-redundant functions in 
tumors and growing/regenerating tissues. Of note, this commitment is present 
even in the absence of tumor burden, as monocyte subsets were isolated from
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tumor-free mice.
The developmental relationship between the two main monocyte subsets remains 
to be clarified. It has been proposed that resident monocytes derive from GR1 + 
inflammatory monocytes (Varol et al. 2007), implying that the two phenotypes may 
represent distinct developmental stages along the monocyte lineage. However, 
neither a genetic defect in nor antibody-mediated depletion of GR1+ monocytes 
affected the generation of GR1- monocytes (Mildner et al. 2007; Alder et al. 2008; 
Scatizzi et al. 2006), suggesting that a direct developmental pathway from a 
multipotent precursor to GR1- monocytes may exists (Yona & Jung 2010). 
Therefore, a better characterization of monocyte precursors and new lineage 
tracking studies will be needed to establish the developmental relationship 
between monocyte subsets and to clarify whether TEMs represent a distinct 
resident monocyte subset.
Taken together, our findings suggest that TEMs represent a circulating reservoir of 
monocytes actively recruited to extra-vascular tissues by non-inflammatory signals 
produced not only by tumors, but also by developing or regenerating tissues. 
Future studies will identify the signals that govern the lineage determination of 
TEMs and their recruitment to sites of active tissue morphogenesis. Live imaging 
analysis (Egeblad et al. 2008) of monocyte/macrophage subsets expressing the 
newly identified cell surface markers (e.g. MRC1, CD11c, LYVE1, TLR4, MHC-II) 
may better clarify macrophage heterogeneity and dynamics in tumors.
14 Role of TIE2 in TEMs
To knock down Tie2 in BM-derived hematopoietic cells, I developed a novel gene 
knock-down platform that effectively protects the hematopoietic compartment from 
potential toxicity consequent to Tie2 silencing in HSCs. Indeed, our previous
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attempts to knock down Tie2 using constitutive LVs did not allow for efficient and 
stable gene silencing in BM-derived cells because of counter selection of 
transduced cells. By using inducible LVs and HSC de-targeting, I demonstrated 
that Tie2 knock-down in BM-derived cells significantly inhibited angiogenesis and 
microvascular perfusion in MMTV-PyMT mice, but did not affect hematopoiesis 
detectably. Remarkably, by targeting the TIE2 receptor in TEMs, I recapitulated 
several features of TEM elimination (De Palma et al. 2005), including: 1) reduced, 
although not drastically, tumor growth; 2) decrease in tumor vascular area; 3) 
unaltered myeloid cell infiltration in tumors. Together, these results suggest that 
TIE2 is a pivotal biological effector and therapeutic target in TEMs.
TIE2 is expressed at very low level in circulating monocytes, but is strongly 
upregulated (up to 100-fold) specifically in perivascular TEMs (De Palma et al.
2008). Unpublished work from our lab indicates that ANG2 neutralization by a 
novel ANG2-specific monoclonal antibody (Brown et al. 2010) impedes the 
transcriptional up-regulation of Tie2 in tumor-infiltrating TEMs (Pucci, Mazzieri). By 
using a conditional genetic knock down strategy, I show here that the up-regulation 
of the TIE2 receptor in peri-vascular TEMs is required for the functional maturation 
of angiogenic blood vessels. ANG2 may thus signal both autocrinally on ECs 
(Augustin et al. 2009) and juxtacrinally on peri-vascular, TIE2+ macrophages, the 
latter scenario being supported by experimental evidence that ANG2 agonistically 
enhances the pro-angiogenic activity of human blood-derived TIE2+, but not TIE2- 
monocytes in vitro (Coffelt et al. 2010b). One can envision that ANG2 expression 
by angiogenic blood vessels (such as those of expanding tumors or developing 
tissues) mediates a self-reinforcing signal on peri-vascular TEMs via the up- 
regulation of the TIE2 receptor, and that such feedback may be essential for the 
execution of productive angiogenesis (Illustration 34 on page 83). Although it 
cannot be excluded that TIE2 up-regulation in TEMs is mediated indirectly by
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ANG2, the specific modulation of the Tie2 mRNA among other angiogenic genes 
observed in TEMs upon ANG2 blockade (Pucci, Mazzieri, unpublished data) 
supports the view that this response is intimately linked to TIE2 signalling. Of note, 
several growth factors -  including ANGs -  can regulate the expression of their 
receptor tyrosine kinases at the transcriptional level via auto-regulatory feedback 
loops (Hashimoto et al. 2004).
Tie2 silencing in TEMs, although consistently inhibiting angiogenesis and tumor 
vessel function by almost 50%, did not reproducibly inhibit tumor growth in MMTV- 
PyMT mice. In this regard, previous reports have shown that the genetic deletion 
of pro-angiogenic factors in ECs or myeloid cells may reduce angiogenesis in 
tumors without decreasing tumor growth rates (Nasarre et al. 2009; Stockmann et 
al. 2008). It should be noted that in my Tie2 silencing studies, as a consequence of 
the chimeric nature of repopulating cells in a BM transplantation setting, a 
significant proportion of the tumor blood vessels were surrounded by enough TIE2- 
competent (OFP-) TEMs to enable sufficient blood vessel growth and consequent 
tumor perfusion in the tumors of amiR(Tie2) mice, thus allowing for unimpeded 
tumor growth. Thus, it cannot be excluded that fully exhaustive Tie2 targeting in 
tumor-infiltrating macrophages would impair angiogenesis and tumor vessel 
functionality to an extent critical for tumor oxygenation, nourishment and growth.
In summary, Tie2 gene silencing data indicate that the TIE2 receptor expressed by 
peri-vascular TEMs is a critical regulator of ANG2-mediated pro-angiogenic 
programs in tumors (Illustration 34 on page 83). Because tumor infiltrating myeloid 
cells are known to convey pro-tumoral and pro-angiogenic programs that can 
counteract the efficacy of anti-angiogenic treatments (Bergers & Hanahan 2008), 
the combined targeting of angiogenic ECs and pro-angiogenic TAMs by selective 
ANG2/TIE2-pathway inhibitors may significantly extend the reach of anti-
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Illustration 34: Model of ANG2-TIE2 interactions modulating the pro-angiogenic activity of TEMs. 
Circulating TEMs express low-level TIE2, but the receptor is up-regulated upon their 
extravasation in the tumor microenvironment Once in the tumor stroma, TEMs adhere to 
sprouting blood vessels, which secrete high-level ANG2. In the presence of ANG2, TEMs 
promote vascular growth and anastomosis. Upon genetic knock-down of Tie2, TEMs fail to 
promote vascular morphogenesis. Because blocking ANG2-TIE2 interactions in TEMs 
phenocopies the anti-angiogenic effects obtained by depleting TEMs, it is suggested here that 
the ANG2-TIE2 signaling axis mediates juxtacrine interactions between TEMs and ECs that are 
required for sprouting angiogenesis.
angiogenic therapy in cancer patients.
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Appendix -  RNA interference
15 The micro-RNA world
RNA interference (RNAi) is endogenously mediated by microRNA (miR), 21-24 
nucleotides non-coding RNA which fine-tunes expression of a large numbers of 
target genes (Bartel 2004). miRs are generated from primary transcripts (pri-miRs) 
generally transcribed from polymerase-ll (Pol-ll) promoters. The genomic location 
of pri-miRs normally is an intronic sequence of either a coding or non-coding gene, 
or an intergenic region (Morlando et al. 2008). Pri-miRs are processed in the 
nucleus by Drosha, an RNase III like enzyme, to -60-70 nucleotides stem-loop 
molecules with two-nucleotide 3' overhangs (pre-miR) (Illustration 35). Drosha 
cleavage occurs during transcription acting on both independently transcribed 
(intergenic) and intron-encoded miRNAs (Morlando et al. 2008). Pre-miRs are 
shuttled by exportin-5, a Ran-GTPase, to the cytosol where Dicer, another RNase 
III like enzyme, releases a 21-24 double-stranded RNA from the stem. This is 
loaded into the RNA-induced silencing complex (RISC), which generally selects 
one of the two strands as the guide strand (mature miR), according to 
thermodynamic properties. RISC targets mRNA with complementary sequence to 
the miR and down-regulates their expression decreasing transcript translation and 
stability by a variety of molecular mechanisms (Eulalio et al. 2008). Because most 
miR::mRNA pairing in mammalian cells is not perfect, direct RISC-dependent 
mRNA cleavage is unusual.
16 Exploiting RNAi
RNAi has proven essential for gene function studies and holds promise for the 
development of new molecular medicines (Chang et al. 2006; Kim & Rossi 2007).
85
microRNA gene or intron Nucleus i Cytoplasm
RNA Pol II /  III
^ 1 I I : 111111h • Ii i i i ii i I ['"jimT 
pri-microRNA
Transcription
DroshaXDGCR8 Cleavage
11 mitirmmrrm Exportin
pre-microRNA
x Nuclear export
5' *
LiJJ-LLLLLLI
pre-microRNA
CleavageDicer 1 TRBP
3' 5'microRNA duplex
fe. U, L L11.1., 1,. Ji „LL,U,l„iU. , J
3' 5'
Ago2
crn in? nun nrrm
Mature microRNA
RISC formation
3'
Degradation
i
\
mRNA target cleavage Translational repression mRNA deadenylation 
Illustration 35: The miRNA processing pathway. The vast majority of primary miRNA transcripts 
(pri-miRNA) are synthesized by RNA polymerase II and then cleaved by the microprocessor 
complex Drosha-DGCR8 (Pasha) in the nucleus. The resulting precursor hairpin, the pre- 
mi RNA, is exported from the nucleus by Exportin-5-Ran-GTP. In the cytoplasm, the RNase Dicer 
in complex with the double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin 
to its mature length. The functional strand o f the mature miRNA is loaded together with 
Argonaute (Ago2) proteins into the RNA-induced silencing complex (RISC), where it guides 
RISC to silence target mRNAs through mRNA cleavage, translational repression or 
deadenylation, whereas the passenger strand (black) is degraded. From Winter et al. Nat Cell 
Biol 2009.
Several hurdles still prevent full exploitation of the biological and therapeutic 
potential of RNAi. Selection of an efficient siRNA sequence still requires empirical
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validation, and safe and effective delivery of RNAi molecules remains an active 
area of investigation (McBride et al. 2008; Li et al. 2007). RNAi off-target effects 
result from one of three mechanisms: 1) stretches of dsRNA can activate non­
specific cellular innate immune responses, such as the interferon and toll-like 
response (Bridge et al. 2003; Fish & Kruithof 2004; Kleinman et al. 2008); 2) 
saturation of the cell RNAi machinery and thereby inhibit the function of 
endogenous miRNAs (Grimm et al. 2006); 3) complementarity to other, non-target 
mRNAs (Birmingham et al. 2006). Ongoing efforts aim to identify which approach 
guarantees the best balance between efficacy and off-target effects, toxicity and 
which expression cassette and delivery vehicle best fit the requirements of stable 
RNAi delivery (Kim & Rossi 2007). Commonly siRNA are transiently delivered to 
target cells by transfection approaches, a constraint that limits the possible 
applications. Hence, other strategies have been pursued to express RNAi 
precursors from within the target cells. Short hairpin RNA mimic the pre-miR 
structure and require Dicer processing in order to be functional. A crucial 
advantage is the possibility to use polymerase-lll promoters for high-level 
expression and stable gene knockdown (Brummelkamp et al. 2002). Although 
polymerase-lll promoters have also been engineered for inducible expression 
(Szulc et al. 2006), they lack the tissue and developmental specificity of Pol-ll 
promoters. Furthermore, concerns about the potential toxicity of this approach 
have been reported due to the possible saturation of miR processing steps and 
consequent interference with endogenous miR regulation (Kleinman et al. 2008; 
Grimm et al. 2006).
Artificial miRs (amiRs) are natural pri-miR in which the stem sequence of an miR 
has been substituted with a sequence targeting the gene of interest. In target cells, 
amiR undergoes the same processing steps of the parental pri-miR (Zeng et al. 
2002). Importantly, amiR can be also transcribed by Pol-ll promoters, like
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endogenous pri-miR, which allows exploitation of state-of-the-art gene expression 
cassettes and may alleviate concerns for over-expression (Boudreau et al. 2009). 
Although many examples in the literature of functional amiR and many of the 
details for making amiR have been worked out, the choice of an optimal pri-miR 
backbone for robust and versatile amiR expression and the criteria for its 
validation are still actively pursued (Aagaard et al. 2008; Ely et al. 2009; Chung et 
al. 2006). In order to co-express RNAi and a selector or therapeutic gene, amiRs 
have been introduced into the 5 - or 3'-untranslated region (UTR) of the transgene 
(Stegmeier et al. 2005). This modification, while improving amiR expression, 
impairs expression of the linked transgene. More recently, amiRs were inserted 
within an intron to maintain expression of the transgene unaltered (Chung et al. 
2006). However, these features of the expression cassette may interfere with 
delivery by y-retroviral and lentiviral vectors (LVs), the preferred systems for stable 
expression in proliferating cells and tissues. Thus, optimization of vector design is 
still required to perform knock down studies in challenging settings, such as 
primary cells.
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Material and methods
17 Transgenic mice
FVB mice were purchased from Charles River Laboratory (Calco, Milan, Italy). 
FVB/Tie2p/e-GFP and FVB/Pgk-rtTA-miR-126T transgenic mice were previously 
generated by lentiviral vector (LV)-mediated transgenesis and established as a 
colony in 2003 at the San Raffaele animal facility (De Palma et al. 2005). 
FVB/MMTV-PyMT mice were obtained from the NCI-Frederick Mouse Repository 
(MD) and established as a colony at the San Raffaele animal facility. Five to 6- 
week-old female MMTV-PyMT mice were transplanted with BM cells from Tie2p/e- 
GFP mice, as described (De Palma et al. 2008), and the tumors analyzed 4 or 6 
weeks after the transplant. Transgenic mice were screened by qPCR of vector 
sequences. Tie2p/e-GFP transgenic mice had LV copy number ranging from 5 to 
10 LV copies/cell. All animal procedures were performed according to protocols 
approved by the Animal Care and Use Committee of the Fondazione San Raffaele 
del Monte Tabor and communicated to the Ministry of Health and local authorities 
according to the Italian law.
18 Lentiviral vectors
To generate the rtTA-m2 encoding vector (LV2), I cloned four tandem copies of a 
21-bp sequence with perfect complementarity to miR-126 (mir-126T) downstream 
to a PGK-GFP LV, as previously described (Brown et al. 2006). I then replaced the 
GFP sequence with the rtTA-m2 cDNA, to obtain the PGK-rtTA-m2-mir-126T LV. 
To generate the amiR encoding vectors (LV1), I replaced the EF1a core promoter 
of the EF1a-amiR(Tie2)-NGFR and EFIa-amiR(Luc)- NGFR LVs (Amendola et al.
2009) with a tetracycline-responsive element (TRE)-containing promoter, and
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further replaced NGFR with OFP, to obtain the TRE-amiR(Tie2)-OFP and TRE- 
amiR(Luc)- OFP LVs, respectively. In these vectors, the amiR sequence is lodged 
in the EF1a intronic sequence downstream to the TRE-containing promoter. The 
siRNAsequences used are: amiR223(Tie2), 5-TTTGCCCTGAACCTTATAC CG-3'; 
amiR155(Tie2): 5'-TACAGGTCCTGCCAAAT GT GT-3'; amiR223(Luc), 5'-
TATTCAGCCCA TAT CGTTT C A-3'; amiR155(LacZ), 5'-
AAATCGCTGATTTGTGTAGTC-3'. The LVs used in this study and cloning strategy 
used for their construction will be available upon request. Concentrated VSV.G 
pseudotyped, third-generation LV stocks were produced and titred as described 
previously (De Palma & Naldini 2002).
19 Hematopoietic stem/progenitor cell (HSPC) isolation, 
transduction and transplantation
Six to 12-week-old female FVB/PGK-rtTA-miR-126T (LV2) transgenic mice were 
killed with C02 and their BM was harvested by flushing the femurs and the tibias. 
Lineage-negative cells (BM-Lin- cells) enriched in HSPCs were isolated from BM 
using a cell purification kit (StemCell Technologies) and transduced by 
concentrated LVs. Briefly, 106 cells/ml were prestimulated for 4-6 hours in serum- 
free StemSpan medium (StemCell Technologies) containing a cocktail of cytokines 
(IL-3 (20 ng/ml), SCF (100 ng/ml), TPO (100 ng/ml) and FLT-3L (100 ng/ml), all 
from Peprotech) and transduced with amiR-expressing LVs (LV1) with a dose 
equivalent to 108 LV Transducing Units/ml, for 12 hours in medium containing 
cytokines. After transduction, 106 cells were infused into the tail vein of lethally 
irradiated, 5.5-week-old, female FVB or FVB/MMTV-PyMT mice (radiation dose: 
1150 cGy split in 2 doses). To induce the expression of the amiR(Tie2) and OFP, 
the transduced cells were cultured in vitro for 2 days in the presence or absence of 
doxycycline (1 pg/ml; Sigma). Transduced cells were also cultured for 5 days to
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measure OFP expression by flow cytometry, or for 9 days to measure the number 
of integrated LV copies/cell genome.
19.1 In vivo doxycycline administration
Starting at 4 weeks after HSPC transplant (i.e., at 9.5 weeks of age), FVB or 
MMTV-PyMT mice were moved to doxycycline-containing food (Charles River) and 
received intra-peritoneal injections of doxycycline (0.5 mg/mouse) every third day, 
until the end of the experiments (12.5 weeks of age for FVB and 15 weeks of age 
for MMTV-PyMT mice).
19.2 Magnetic Resonance Imaging (MRI)
MRI examinations of MMTV-PyMT transgenic mice were performed on a 3.0 Tesla 
human scanner (Achieva 3T, Philips Medical Systems, the Netherlands), equipped 
with 80 mT/m gradients and a 40 mm volumetric coil (Micro-Mouse 40, Philips 
Medical Systems, the Netherlands). The mice were anaesthetized with Avertin and 
maintained on Sevoflurane (2% for maintenance), in a 95-98% 02 mixture. During 
acquisition, mice were positioned prone on a dedicated temperature control 
apparatus to prevent hypothermia. For mammary gland imaging, a Turbo Spin 
Echo T2 (TR = 2500; TE = 80; turbo-factor = 9; FOV = 65x65mm; zero-filled 
voxelsize 100 x 100 x 800 micron) was acquired at 10.5 and/or 14.5 weeks of age. 
The larger field of view allowed evaluation of all five couples of mammary glands. 
Tumor volumes were calculated on a separate workstation (ViewForum 2.0) after 
manual segmentation of the lesion on the basis of signal intensity variation and 
enhancement characteristics, by summing individual volumes (calculated as lesion 
area x slice thickness) in each slice.
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20 Tumor models
20.1 Spontaneous MMTV-PyMT tumors
For Tie2 gene knock-down experiments, HSPC transplantation was performed at 
5.5 weeks of age, as described above. To induce OFP and Tie2 gene knock-down, 
the mice received doxycycline administrations (see paragraph 19.1) starting at 4 
weeks post-HSPC transplantation (i.e., 9.5 weeks of age). Mammary tumors were 
monitored at weekly intervals and either measured by magnetic resonance 
imaging (MRI)- based volumetry (performed 10.5 and/or 14.5 weeks of age; see 
below) or tumor weight measurements performed at necropsy (15 weeks of age). 
At the end of the experiments, mice were anesthetized by Avertin and euthanized 
by intracardiac perfusion of PBS.
20.2 N202 mouse mammary carcinoma
The N202 mammary carcinoma cell line was cultured under standard conditions 
and 5x106 cells were implanted subcutaneously in 9.5-week-old, female FVB mice 
transplanted 4 weeks earlier with transduced HSPCs (see above). To induce OFP 
and Tie2 gene knock-down, the mice received doxycycline administrations (see 
paragraph 19.1) starting 2 days after tumor cell injection. Tumors were analyzed 3 
weeks post-tumor cell injection.
21 Flow cytometry
Flow cytometry either used a CyAn ADP (DAKO) or a BD FACSCanto (BD 
Bioscience) apparatus.
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21.1 Antibodies
Official Alias Origin Purchased by Conjugation / Secondary
name
Tek Tie2 Rat eBiosciences
antibodies
PE
Csflr CD115 Rat Serotec PE
Itgam CD11b Rat BD FITC, PE, APC
Sell CD62L Rat BD APC
Tlr4 Ly87 Rat BD Biotinylated / Streptavidin-PE
Mrc1 CD206 Goat R&O Unconj. / Donkey anti-goat
Xlkdl Lyvel Rat MBL
Alexa633
PE
Ly6c1 Ly6C Rat SouthernBiotech PE
Ly6g Ly6G Rat BD PE
Emr1 F4/80 Rat Serotec PE, APC
GR1 Ly6C/G Rat BD PE, APC
Pecaml CD31 Rat BD APC
CD 163 Rabbit Santa Cruz Unconj. / Donkey anti-rabbit
CD48 SLAMF2 Rat BD
Alexa647
PE
114ra CD 124 Rat BD PE
Itgax CD11c Rat BD PE
CD86 B7.2 Rat BD PE
Itga4 CD49d Rat BD PE
Fcerla FceRI Rat eBiosciences PE
Spn CD43 Rat BD PE
Tlr2 Ly105 Rat BD Biotinylated / Streptavidin-PE
Itga2b CD41 Rat BD PE
c-kit CD117 Rat BD APC
c-kit CD117 Rat eBiosciences APC-Alexa750
Sca-1 Ly-6A/E Rat BD PE
lgG1 Rat eBioscience PE, APC
lgG2a Rat BD PE, APC
lgG2a Rabbit Molecular Unconj. / Donkey anti-rabbit
lgG2a Goat
Probes 
Santa Cruz
Alexa647
Unconj. / Donkey anti-goat
Alexa633
Table 5: List of antibodies for flow cytometry
21.2 Tumors
N202 mammary tumors were grown subcutaneously for 4-6 weeks in the right 
flank of 6-8-week old Tie2p/e-GFP transgenic or control FVB mice. For each 
analysis, 3-5 tumors were excised and made into single cell suspensions by
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collagenase IV (0.2 mg/ml, Worthington), dispase (2 mg/ml, Gibco) and DNasel 
(0.1 mg/ml, Roche) treatment in IMDM medium supplemented with 5% fetal calf 
serum (FCS), glutamine and antibiotics. After 1h at 37°C in a shaking bath, the cell 
suspension was 40 pm-filtered and washed in phosphate buffered saline (PBS) 
containing 2mM EDTA and 0.5% bovine serum albumin (BSA). Cell suspensions 
were incubated with rat anti-mouse FcylM/ll receptor (CD16/CD32) blocking 
antibodies (4 pg/ml), labeled with 7-amino-actinomycin D (7AAD) to stain 
nonviable cells and then stained using the antibodies listed in Table 5. To gate 
GFP+ cells, I used cells isolated from wild-type FVB mice.
21.3 Peripheral blood
Peripheral blood was collected from the tail vein of Tie2p/e-GFP transgenic or 
control FVB mice. After lysis of red blood cells using the TQ-Prep workstation 
(Beckman-Coulter), leukocytes were stained with 7AAD, incubated with rat anti­
mouse Fcylll/ll receptor (CD16/CD32) blocking antibodies (4 pg/ml) and then 
stained using the antibodies listed in Table 5. To gate GFP+ cells, I used cells 
isolated from wild-type FVB mice.
22 Flow sorting
22.1 Tumor-derived TEMs, TIE2- TAMs and ECs
TEMs and TIE2- TAMs were isolated from N202 mammary tumors grown 
subcutaneously for 4-6 weeks in the right flank of 6-8-week old Tie2p/e-GFP 
transgenic mice. For each cell sorting session, 10-30 tumors were excised and 
made into single-cell suspensions by collagenase IV (0.2 mg/ml, Worthington), 
dispase (2 mg/ml, Gibco) and DNasel (0.1 mg/ml, Roche) treatment. Cell 
suspensions were then stained with PE-conjugated anti-CD11b and APC-
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conjugated anti-CD31 monoclonal antibodies (BD Pharmingen), and the CD11b+ 
myeloid cells magnetically enriched using anti-PE microbeads and LS columns 
(Miltenyi). After magnetic enrichment, the vast majority of the cells were 
CD11b+CD31-. To isolate tumor-derived ECs, N202 tumors were processed as 
above, but the CD11b+ cell enrichment step was omitted. To sort cells, I used a 
Vantage DiVa apparatus (Becton-Dickinson). Before sorting, single-cell 
suspensions were labeled with 7-amino-actinomycin D (7AAD) to stain nonviable 
cells. I isolated TEMs as 7AAD- CD11b+ CD31- GFP+ cells (n=7 independent cell 
sorting) and TIE2- TAMs as 7AAD- CD11b+ CD31- GFP- cells (n=7). As 
fluorescence minus one (FMO) sample I used CD11b-enriched cells obtained from 
tumors grown in wild-type FVB mice. Tumor-derived ECs were sorted as 7AAD- 
CD11b- CD31+ GFP+ cells (n=3).
22.2 GR1+ CD11b+ myeloid derived suppressor celis (MDSCs)
MDSCs were isolated from the spleen of N202 tumor-bearing Tie2p/e-GFP 
transgenic mice as GR1+ CD11b+ cells. For each cell sorting session, 3 spleens 
were made into single-cell suspensions by mechanical treatment and then stained 
with PE-conjugated anti-CD11b and APC-conjugated anti-GR1 antibodies.
22.3 Peritoneal macrophages (PMs)
PMs were obtained from tumor-free FVB mice by peritoneal lavage with 10 
ml/mouse serum-free RPMI. For each cell sorting session, I used 15, 6-to-8-week 
old mice. Recovered cells were stained with FITC-conjugated anti-CD11b, APC- 
conjugated anti-CD31 and PE-conjugated anti-F4/80 antibodies before cell sorting. 
PMs were sorted as F4/80+ CD11b+ CD31-cells (n=2).
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22.4 Resident and inflammatory monocytes
For each experiment, blood was collected by cardiac puncture from 20 deeply 
anesthetized (Avertin) FVB mice. Peripheral blood mononuclear cells were purified 
with Lympholyte-Mammal (Cedarlane Labs, Canada). After staining with PE- 
conjugated anti-CD115 and APC-conjugated anti-GR1 antibodies and 7AAD vital 
staining, resident and inflammatory monocytes were sorted as 7AAD- CD 115+ 
GR1- and 7AAD- CD 115+ GR1+ cells, respectively, to a purity > 95% (n=4).
23 Immunofluorescence staining (IFS) and confocal 
microscopy
Tumors, liver samples and whole embryos (see below) were made into 12-16 pm 
cryostat sections, as described (Venneri et al. 2007). Briefly, tumors, embryos and 
organs were fixed for 1-4 hr in paraformaldehyde, equilibrated for 12 hr in PBS 
containing 15% sucrose, 24 hr in PBS/20% sucrose, and eventually 48 hr in 
PBS/30% sucrose. The samples were then embedded in O.C.T. compound for 
quick freezing in liquid nitrogen. Cryostat sections were laid on slides and 
immediately stained; when required, slides were frozen at -80°C. For 
immunofluorescence staining, sections were blocked with 5% serum (Vector 
Laboratories, Burlingame, CA) in PBS containing 1% bovine serum albumin (BSA) 
and 0.1% Triton X-100 (PBS-T). For staining, I used the antibodies listed in Table 
6. Both unconjugated and directly conjugated antibodies were used; secondary 
antibodies were used to reveal unconjugated antibodies. Nuclei were stained by 
TO-PRO-3 (Molecular Probes). Confocal microscopy used an Axioskop 2 plus 
direct microscope (Zeiss) equipped with a Radiance 2100 three-laser confocal 
device (BioRad, Segrate, Italy). Axioskop 2 microscope used Zeiss W-PI 10x/0.23 
or Zeiss Plan-Neofluor 20x/0.5 numerical aperture objective lens. Fluorescent
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signals from the individual fluorophores were sequentially acquired from single 
optical sections and analyzed by Paint Shop Pro X (Corel, Ottawa, Canada), as 
described previously (Venneri et al. 2007).
23.1 In vivo labeling of vascular perfusion
To detect perfused blood vessels, 10 min. before anesthesia (Avertin) I intra­
venously injected 50 pg/mouse of FITC-conjugated, Lycopersicon esculentum 
lectin (Vector Labs Inc., Burlingame, CA). Once anesthetized, the mice were 
perfused by intra-cardiac infusion of 10-15 ml of PBS containing 2% Eparin to 
wash out blood cells and excess lectin.
23.2 Quantification of vascular parameters
To analyze angiogenesis/vascular perfusion in transgenic MMTV-PyMT models, 3- 
6 tumors/group, 8-15 sections/tumor and 1 -3  images/section were analyzed. 
Images were scanned at x400 or x100 magnification by a confocal microscope 
(Radiance 2100; BioRad) and digitally processed with ImageJ (NIH) to measure 
the marker-positive area. Counts were averaged to determine the relative vascular 
area or the marker-positive area. Error bars represent SEM.
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23.3 Antibodies
Official
name
GFP
GFP
Alias Origin
Rabbit
Purchased Conjugation I Secondary 
by antibodies
Molecular Unconj. / Donkey anti-rabbit
Probes 
Chicken Abeam
Alexa488
Unconj. / Donkey anti-chicken 
Alexa488
Tek Tie2 Rat eBiosciences PE
CD68 Rat Serotec Unconj. / Goat anti-rat Alexa546
Ptprc CD45 Rat BD PE
Pecaml CD31 Rat BD PE, APC
Emr1 F4/80 Rat Serotec PE, APC
Mrc1 CD206 Goat R&D Unconj. / Donkey anti-goat
Alexa546
Xlkdl Lyvel Rabbit MBL Unconj. / Donkey anti-rabbit
Alexa488 / 546
CD163 Rabbit Santa Cruz Unconj. / Donkey anti-rabbit
Alexa488
Stabl Mouse NA Biotinylated / Streptavidin-PE
lgG1 Rat eBioscience PE, APC
lgG2a Rat BD PE, APC
Table 6: List of antibodies for IFS 
24 Colony-forming cell (CFC) assays
CFC assays were performed from either FACS-sorted cells (tumor-derived TEMs 
and TIE2- TAMs; Tie2p/e-GFP+ CD11b+ and Tie2p/e-GFP- CD11b+ embryonic 
macrophages), unfractioned BM cells or BM-derived lineage-negative (Lin-) cells. 
Unfractioned BM cells were obtained from 6 week-old mice by flushing their 
femora and tibiae. Lin- cells were isolated from unfractioned BM cells using a kit 
from StemCell Technologies. I plated 5 x 103, 2 x 104 and 1 x 105 cells in a 
methylcellulose-based medium (MethoCult M3434, from StemCell Technologies) 
and allow the colonies to grow for 15 days before scoring them under an inverted 
microscope.
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25 May-Grunwald-Giemsa staining
May-Grunwald-Giemsa staining was performed on flow sorted cells (tumor-derived 
TEMs and TIE2- TAMs; Tie2p/e-GFP+ CD11b+ and Tie2p/e-GFP- CD11b+ 
embryonic macrophages). Briefly, I prepared 3 slides for each cell population, by 
centrifuging 1 x 105 (2 slides) and 5 x 104 (1 slide) sorted cells onto the slide. After 
cytospin, cells were stained using a standard May-Grunwald-Giemsa staining 
protocol. For each cell population, at least 25 photos were randomly acquired 
under a direct microscope (Zeiss) and morphologic analysis of the cells performed 
with the advice of a professional pathologist.
26 Gene expression analyses and statistical analysis
26.1 Comparison of gene expression profiles between tumor-derived cells 
vs. circulating monocytes
The expression of a panel of 39 genes (selected among those analyzed in tumor- 
derived cells) was analyzed in both resident and inflammatory monocytes by 
qPCR, as described above. The 39 analyzed genes were either upregulated, 
downregulated or not differentially expressed between tumor TEMs and TIE2- 
TAMs. Twenty-two out of 39 genes displayed coordinated expression in tumor 
TEMs/TIE2- TAMs vs. resident/inflammatory monocytes (n=4 independent 
experiments). To test whether this outcome results by chance, I performed an 
Exact binomial test. Since the case to have a concordant expression is 1 out of 3 
possible situations (upregulated, downregulated, not differentially expressed), the 
null hypothesis is assumed H0: p=1/3, p being the probability of a random 
occurrence of concordant events. The two-sided test for 22 successes in a 
sequence of 39 independent experiments, with the hypothesized probability of 
success explained above, is computed, leading to a p-value = 0.003. Thus, I reject
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the null hypothesis and consider the “concordance” as not random.
27 RNA and DNA extraction and qPCR
27.7 Gene expression (mRNA)
Sorted cells obtained from N202 tumors were lysed for long RNA extraction using 
the RNeasy Micro kit (Qiagen). Briefly, after cell sorting, 2.5-10 x 104 cells were 
obtained from each independent cell sorting (see above) and washed in low- 
protein buffer. Long RNA was purified following the RNeasy Micro kit guidelines 
(Qiagen). RNA was retrotranscribed with Superscript III (Vilo kit, Invitrogen). All 
qPCR analyses were performed with TaqMan probes from Applied Biosystems. 
qPCR was run for 45 cycles in standard mode using an ABI7900HT apparatus 
(Applied Biosystems).
27.1.a Freshly isolated TEMs, TIE2- TAMs, MDSCs, PMs and ECs
To obtain adequate amounts of cDNA for each gene profiling experiment 
(interrogating 280 individual genes), 1 to 3 cell sorting sessions were performed. 
All qPCR analyses were performed with TaqMan probes from Applied Biosystems, 
apart from Th1-Th2 in vitro stimulation experiments, which used Sybrgreen 
mastermix from Applied Biosystems and designed primers (see paragraph 27.1.b 
below). I either used individual TaqMan gene expression assays to analyze 
expression of individual genes, or multi-gene TaqMan low density arrays. I used 2 
custom and 1 pre-made (Immune Panel) TaqMan low density arrays, each 
measuring the expression of 96 genes in 4 technical replicates. One hundred ng -  
1 pg of cDNA was loaded on each array. qPCR was run for 35 (low density arrays) 
or 40-45 cycles (individual gene analyses) in standard mode using an ABI7900HT 
apparatus (Applied Biosystems).
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27.1.bln vitro stimulation of TEMs, TIE2- TAMs and PMs with Th1 and Th2 
cytokines
Adherent PMs (purity >95% after cell sorting) and tumor-derived TEMs were 
incubated for 30 minutes at 37° in complete RPMI with 10% fetal calf serum. Th1 
polarization was stimulated by priming cells with IFNg (0.05U/ml, Sigma) for 30 
minutes, followed by stimulation with LPS (100ng/ml). Th2 responses were 
induced by stimulating cells with IL4 (20ng/ml, Peprotech). After 4 hours of 
stimulation, cells were washed and lysed for RNA extraction and qPCR analysis. 
qPCR used Sybrgreen mastermix from Applied Biosystems and the primers listed 
in Table 7.
Gene Fw Rv
Arg1 CAGAAGAATGGAAGAGT CAGT G GCAGCTATGCAGGGAGTCACCC
Cell 7 AGTGCTGCCTGGATTACTTCAAAG CTGGACAGT CAGAAACACGATGG
Nos2 TGGTCCGCAAGAGAGTGCT CCTCATTGGCCAGCTGCTT
1112a GGAAGCACGGCAGCAGAATA AACTT GAG G G AG AAGTAG G AAT G 
G
B2m CATGGCTCGCTCGGTGACC AATGTGAGGCGGGTGGAACTG
Table 7 Primer sequences
27.1.c Circulating inflammatory and resident monocytes
To perform multiple qPCR assays on the limited amount of starting material 
obtained from circulating monocyte subsets, a pre-amplification step was done on 
cDNA using TaqMan PreAmp MasterMix (AppliedBiosystems). Briefly, up to 100 
TaqMan assays were pooled and diluted 1:100 in water. This mix has been used to 
pre-amplify the genes of interest in a PCR as follows: 10 min 95°, 14 cycles of 15 
sec at 95° and 4 min at 60° in a 50pl reaction volume. After pre-amplification, the 
samples were diluted 1:5 and used as template to quantify the genes of interest in
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a standard TaqMan-based qPCR. I validated this procedure on non-limiting 
samples (data not shown) and found that >92% of the genes gave a AACT value 
within ±1.5 with respect to the non-amplified sample. These results indicate that 
the pre-amplification step did not bias the mRNA composition (i.e. the relative 
proportion of each mRNA) in our samples.
27.2 Small RNA (including artificial micro RNA) analysis
To purify small RNA from BM-derived, LV2-transgenic/LV1- transduced HSPCs, I 
followed miRNeasy Mini kit guidelines (Qiagen). Two days after LV1 transduction 
in the presence or absence of doxycycline, the cultured cells were collected, 
extensively washed and lysed for total RNA extraction using the miRNeasy Mini kit 
(Qiagen). To retrotranscribe small RNAs, I used High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) and a custom, small RNA reverse 
transcription primer specific for the mature form of amiR(Tie2) sequence (Applied 
Biosystems). To perform qPCR on retrotranscribed small RNAs I used inventoried 
(for miR-16 and Let7a) or custom (for amiR(Tie2)) TaqMan small RNA assays 
(Applied Biosystems).
27.3 Vector copy number analysis
For vector copy number (VCN) analysis, I purified genomic DNA from circulating 
blood or BM cells using a Maxwell-16 instrument (Promega) and performed qPCR 
using custom TaqMan assays specific for pactin, rtTA-m2 or OFP sequences 
(Applied Biosystems). Standard curves for the rtTA-m2 and OFP sequences were 
obtained from PGKrtTA- miR-126T transgenic mice and a cell line transduced with 
an OFP-expressing LV, respectively. The VCN of genomic DNA standard curves 
was determined using custom TaqMan assays specific for LVs (Applied 
Biosystems).
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27.4 Collection of raw data and determination of gene expression and LV 
copy number
The SDS 2.2.1 software was used to extract raw data (CT) and to perform gene 
expression or VCN analysis. In the Sybr-based qPCR experiment (see paragraph
27.1.b), after the qPCR run I performed a dissociation curve. Wells with more than 
one amplicon were discarded. To determine gene expression, the difference (ACT) 
between the threshold cycle (CT) of each gene and that of the reference gene 
(B2m for multi-gene arrays and in vitro stimulation experiments; Gapdh for 
individual gene assays; both B2m and Gapdh for analyses of circulating 
monocytes; Let7a for small RNA analysis) was calculated by applying an equal 
threshold (0.02 for all the genes inside the TaqMan low density arrays, 0.1 for all 
the pre-amplified genes). The ACT of different genes can be compared only when 
an equal threshold is applied to calculate the CT. The lower the ACT, the higher the 
gene expression level.
To calculate VCN I used the following formula: VCN = VCN(standard curve) * ng of 
"LV of interest" / ng of pactin; where "LV of interest" is either rtTA-m2 or OFP.
27.5 Calculation of PCR efficiency
The SDS 2.2.1 software was used to extract raw data (C t and raw fluorescence). 
For multi-gene arrays, I calculated PCR amplification efficiency using Miner 
algorithm (http://www.miner.ewindup.info/miner/) and non-baseline subtracted 
fluorescence data. For each gene, I used the mean PCR efficiency calculated 
throughout the samples (TEMs, TIE2- TAMs, PMs, MDSCs). Before averaging, 
single amplification runs that met one of the following conditions have been filtered 
out, because they could represent background amplification: (i) less than 5 
regression windows; (ii) LogA value less than 0.5; (iii) LogPvalue equal to 0; (iv) CT 
greater than 35.
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27.6 Statistical analysis of gene expression data (fold change)
To calculate the fold-change of gene expression, I implemented an analysis of 
covariance model (ANCOVA). This multiple regression approach is aimed at 
modelling jointly the impact of different explicative covariates on the outcome of 
interest. The implemented model leads to a procedure equivalent to test the AACT 
(Yuan et al. 2006). The advantage of this procedure with respect to two-by-two t- 
test comparisons lies in the joint nature of the modeling of all covariates, which 
allows minimizing type I errors (false positive results). Estimation technique is 
based on Likelihood Ratio Test. The model is implemented in R-statistical software 
(version 2.6.1; see http://www.R-project.org). Significance level is chosen at a =
0.05.
27.6.a TEMs vs TIE2- TAMs and Ly6C- vs Ly6C+ monocytes
In this case, the outcome variable is eCt, the efficiency-corrected CT, and the 
covariates are the Sample type (i.e. TEMs or TIE2- TAMs; XSamPie), the Experiment 
(i.e. biological replicates; XExp), the Card (i.e. individual array; Xcard), the Gene 
(Xgene) and the pre-amplification (only for the analysis of gene expression in 
monocytes; Table 2 in the main text). The multiple regression formula is CT ■ 
log2(1+E)=ECT = l3o + pi ' XsamPle $2 ' XExP ft3 ’ Xcard ($4 ' XGene @5 ’ XGene’SamPle 
€, where CT is the threshold cycle, E is the gene-specific PCR efficiency, ECr is the 
efficiency-corrected CT, /3, are the coefficients calculated by the model that 
represents the impact of the respective qualitative variable X, £ is the residual 
error. X  is set to zero when Sample=TIE2- TAMs, Exp = “first replicate”, Card = 
“first array” and Gene = B2m. I chose B2m as the most stable gene by GeNorm 
analysis.
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27.6.bOFP+ vs. OFP- TEMs
In this case, I measured the Tie2 and /32m (reference gene) mRNA in 2 
(amiR(Tie2)) or 3 (amiR(Luc)) biological samples and 6 (for Tie2) or 3 (for (32m) 
technical replicates/biological sample. Being the CT the outcome variable, the 
covariates are the sorted subset (TEMs and TIE2- TAMs), the mouse (i.e., 
biological replicate), the qPCR plate (multi-plate experiment), the gene ( Tie2 or 
B2m) and the amiR (i.e., amiR(Tie2) or amiR(Luc)). The multiple regression 
formula reads as follows:
C t  Po P i ' Xsubset’*" P2 ' Xiviouse P3 ' Xp|ate (^ 4 " XGene*amiR £
where CT is the threshold cycle, pi are the coefficients calculated by the model that 
represents the impact of the respective qualitative variable Xj, with j being each of 
the covariates, and z the residual error.
27.6.C Hematopoietic stem/progenitor cell cultures
In these cases the analyses were performed using qBase excel macro 
(BioGazelle). Calculation of amiR(Tie2) levels in HSPC liquid cultures, either 
treated with doxycycline or left untreated (calibrator). Let7a was used as a 
reference miR. Calculation of Tie2 mRNA levels in HSPC liquid cultures, either 
treated with doxycycline or left untreated (calibrator). p2m was used as reference 
gene. In these experiments, doxycycline was added after washing out LV1; cells 
were analyzed 2 days after transduction. Error bars represent 95% confidence 
interval (1.96*SEM).
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Acronym Index
7AAD -  7-Amino-Actinomycin D 
amiR -  artificial micro-RNAs 
ANG -  angiopoietin 
bEnd -  brain endothelial cells 
BM -  bone marrow
BM-Lin—  BM-derived lineage-negative cells
CFC -  Colony-forming cell
Csf1 -  colony stimulating factor-1
DCs -  dendritic cells
deM(ps -  definitive embryonic Mcps
dpc -  days post coitum
ECs -  endothelial cells
EF1a -  elongation factor 1a
EPCs -  endothelial progenitor cells
FGF -  fibroblast growth factor
GCV -  Gancyclovir
HA -  hyaluronic acid
HCs -  hematopoietic cells
HSC -  hematopoietic stem cells
HSPCs -  hematopoietic stem/progenitor cells
IFS -  immunofluorescence staining
LacZ -  Beta-galactosidase
LCs -  Langerhans cells
Luc -  luciferase
LVs -  lentiviral vectors
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MDSCs -  myeloid derived suppressor cells
miR -  microRNA
MMP -  matrix metalloproteinase
MMTV-PyMT -  mouse mammary tumor virus promoter-polyoma virus middle T 
antigen
MP -  mononuclear phagocytes 
MRI -  Magnetic Resonance Imaging 
Mcps -macrophages
NGFR -  low affinity nerve growth factor receptor
OFP -  orange fluorescent protein
peMcps -  primitive embryonic Mcps
PGK1 -  phospho-glicerate kinase 1
PMs -  peritoneal macrophages
pre-miR -  precursor miR
pri-miR -  primary micro-RNA
RES -  reticulo-endothelial system
RISC -  RNA-induced silencing complex
RNAi -  RNA interference
rtTA- reverse Tetracycline transactivator
SDF1 -  stromal cell derived factor-1
siRNA- short interfering RNA
TAMs -  tumor-associated Mcps
TEMs -  Tie2-expressing macrophages
Tie2p/e -  promoter and enhancer from the Tie2 gene
TK -  Tymidine Kinase
TRE -  Tetracycline responsive element
VCN -  vector copy number
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VEGF -  vascular endothelial growth factor
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